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HSE Foreword for the Naloxone Demonstration Project 
Naloxone is a semi-synthetic competitive opioid antagonist medication recommended by the 
World Health Organisation (WHO) for the treatment of Opioid overdose. In 2014 the WHO 
released guidelines recommending that ‘People likely to witness an opioid overdose should 
have access to naloxone and be instructed in its administration to enable them to use it for the 
emergency management of suspected opioid overdose’. Ireland has one of the highest rates of 
drug overdose in Europe and in 2013 in 42% of deaths where heroin was implicated the 
individual was not alone when the drug was taken. This represents a situation where, in line 
with WHO recommendations, a specific intervention with Naloxone could have saved a life. 
The Naloxone Demonstration Project is therefore both a response to the WHO 
recommendations and also a response to Action 40 of the National Drugs Strategy (2009-
2016) aimed at tackling the harm caused by the misuse of drugs. This was also a key action of 
the 2015 HSE Primary Care, Social Inclusion operational plan. 
 The project aimed to provide training in four locations around the country in relation to the 
recognition of and response to an overdose occurring due to opioid drugs. Training was 
provided to service users, service providers, family members and front line workers. In addition 
there was an active Train the Trainer component to the programme. During the project, close 
to 600 people received training and 31 people participated in the ‘Train the Trainers’ 
component of the project. Six General Practitioners were involved in the medical assessments 
and prescribing of 95 prescriptions of naloxone. Most importantly the evaluation notes that 
five administrations of naloxone occurred resulting in the prevention of five potentially fatal 
overdoses. 
An important element of the demonstration project is this external evaluation that documents 
and reports on the implementation of the complete programme. As both a process and 
outcome evaluation this document represents a comprehensive overview of the naloxone 
demonstration project utilising qualitative and quantitative research methods. The final report 
presented here clearly demonstrates the significant benefits delivered to service users, service 
providers and family members alike. Credit must go to the reviewers for producing such a high 
quality piece of work that will have ongoing implications for the HSE Addiction services for 
years to come. 
I am pleased to accept this evaluation and welcome the very positive findings. Particular thanks 
must go to Dr Denis O’Driscoll, Chief Pharmacist HSE Addiction services, who led and 
managed the whole project in an extremely professional and effective manner. Without his 
dedication and enthusiasm the project would not have been the success that is evident in this 
evaluation. The HSE Primary Care/ Social Inclusion division will continue to support the roll-
out of the recommendations and the project in the knowledge that this initiative will result in 
further saving of lives. 
Dr Eamon Keenan 
National Clinical Lead HSE Addiction Services 
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Executive Summary 
Naloxone is a medicine recommended by the World Health Organisation for treatment in 
opioid overdose cases.  It acts by reversing, within minutes, the effects of opioid overdose. Its 
efficacy has been proven internationally.   
The Naloxone Demonstration Project was established by the Health Service Executive (HSE) in 
2015 to test the feasibility of making Naloxone available for use by opioid users in order to 
prevent death from overdose.  The Demonstration Project falls under Action 40 of the National 
Drugs Strategy (2009-2016) which aims to tackle the harm caused by misuse of drugs. The 
Naloxone Demonstration Project fits within all four tiers of service provision in the National 
Drug Rehabilitation Implementation Committee’s (NDRIC) framework and, in lay administration 
it has potential to be particularly useful in tiers one and two. 
Ireland has one of the highest drug overdose rates in Europe.  Opioids alone accounted for 7% 
of all ‘poisoning deaths’ in 20121 and opioid related deaths (ORDs) made up of single drug and 
poly-drug frequency was 220 (263 in 2011). Forty-two percent of people who died deaths 
where heroin (injecting or smoking) was implicated were not alone at the time they took the 
drug2.  This suggests that there may have been an opportunity to prevent these deaths 
through the administration of Naloxone. 
The product used in the Naloxone Demonstration Project was Prenoxad ™ (1mg/ml injection).  
It was made available in consultation with the Health Products Regulatory Authority (HPRA) 
and the Department of Health (DoH) as an unlicensed medicine as it has additional labelling to 
allow for lay administration in the Summary of Product Characteristics (SmPC). It is injectable, 
administered via the parenteral route and formulated in a specific overdose pack. Each pre-
filled syringe contains five doses of Naloxone.  The intention was that after a single individual 
use this use would be reported in accordance with agreed practice.  The pack would be then 
be then discarded appropriately and the patient referred to their agreed point of contact for 
replenishment.  
 
The Chief Pharmacist, Addiction Services, HSE, was authorised to lead and manage the 
Demonstration Project.  All supplies of Naloxone were channelled through the Project Lead 
who was responsible for all procurement and replenishment of supply. The Naloxone Quality 
Advisory Group (QAG) was established to oversee the implementation of the project. 
Four locations were selected for the Demonstration Project - Dublin, Waterford/South East, 
Limerick and Cork.  The Train the Trainer programme was delivered and representatives from 
each location attended. The rollout progressed steadily in Dublin and Limerick and moved 
more slowly in Cork and Waterford.   
 
                                                 
1
 HRB, 2014, ‘Drug-related deaths and deaths among drug users in Ireland’, Dec 2014 
2 http://www.hrb.ie/uploads/tx_hrbpublications/NDRDI_web_update_2004-2013.pdf 
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Factors that supported the speed of rollout in a given location included prior awareness of and 
engagement with the Project, presence of local champions, belief in the potential of Naloxone 
and the Project to make a difference, proximity to the Project leadership, willingness and 
capacity of local GPs to engage and support from the National Family Support Network. 
 
A central element of the Demonstration Project was the formal briefing of drug users and 
training of those close to them (e.g. service providers, front line workers and family members) 
in the use of Naloxone and in recognising and effectively managing overdose events. A Train 
the Trainers component was also included for frontline staff in services. A full suite of training 
resources was developed. 
 
Thirty-one individuals took part In the Train the Trainers component of the training.  As of 
August 2015, 492 people took part in multi-disciplinary, multi-agency training sessions with 
more groups trained subsequently resulting in close to 600 people in total receiving the 
training. 
 
A total of 95 prescriptions of Naloxone were issued during the Demonstration Project.  The 
majority (67%) of these were issued in Dublin and the remainder (33%) were issued in Limerick.  
Six GPs in total were involved in the medical assessment and prescribing of these 
prescriptions3.  During the time of the Demonstration there were no prescriptions issued from 
the other two Demonstration locations, Waterford and Cork.  Prescriptions in Waterford 
commenced subsequently.  
 
During the course of the Demonstration Project there were five administrations of Naloxone 
and potentially fatal overdoses were prevented for the five males involved.  Four of the 
Naloxone administrations were administered by front line workers and one was administered 
peer to peer.  All had participated in the Naloxone training delivered during the Demonstration 
Project.  
 
In each of the incidents the Naloxone was administered to a person other than to whom it had 
been prescribed.  This suggests that the availability of and easy access to Naloxone was crucial 
to the successful reversal of overdose.  In two instances more than one dose of Naloxone was 
administered from the five dose syringe.  This was judged necessary during the wait for the 
ambulance to arrive and deemed to work well.  
 
In all instances an ambulance was called and at least one person or staff member remained 
with the patient until emergency services arrived as recommended during the training. In two 
instances the patient was admitted to hospital and discharged after a short period of 
observation. 
 
 
 
                                                 
3 Five in Dublin and one in Limerick 
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The front line workers managed the situations effectively and followed through on the precise 
steps that they had learnt and practiced during their training. Three of these were interviewed 
soon after the incident and all indicated a sense of pride and relief, empowerment and 
enhanced confidence to manage these types of situation. 
 
The activation and engagement of a full range of stakeholders in the Demonstration Project 
was supported by the open and inclusive approach and communication from the outset. There 
was a partnership way of working between community and voluntary sector and the HSE and 
raising awareness of Naloxone within NDRIC and social care and community networks. Family 
members and the National Family Support Network were included and actively involved. There 
was openness to learning and constructive criticism which supported continuous improvement. 
 
Feedback from stakeholders also points to areas that require attention.  These include 
adopting a more measured and strategic approach to consultation post Demonstration. The 
drawing in of the full suite of stakeholders, especially those who doubt the Project, is an 
important success determinant.  Some organisations and/or stakeholder groups are more 
cautious with respect to delivery of new programmes and need time to assess potential impact 
on their current service delivery. The presence and involvement of service user networks and 
organisations within the communication about Naloxone could be strengthened. More time 
could be invested in consultation pre implementation through formal and structured 
engagement with specific groups, e.g. service users, family members, GPs, trainers, etc. This 
would benefit from the support of a centre point of communication to manage ongoing 
consultation, briefings and PR during implementation. 
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The recommendations are summarised below and are set out in priority order of necessary 
action. Chapter Five contains the detailed rationale for each recommendation. 
 
Recommendation One - Communication & Consideration 
 
1.1  The results of this report should be discussed, early in 2016, within the QAG and the 
National Social Inclusion Unit within the HSE, to inform the action plan for the future. 
 
Recommendation Two - Governance 
 
2.1  The QAG should be strengthened by broadening its membership to include wider 
clinical expertise and clinical governance and more regional representation.   
 
2.2  The terms of reference of the QAG should be revisited and revised accordingly. 
 
2.3  The QAG should discuss possible options as to the best way forward for Naloxone and 
agree the strategy to achieve this, accompanied by an action research plan overseen by 
the QAG. 
 
Recommendation Three - Planning and Preparation for Future Roll Out 
 
3.1  The roll out of Naloxone should continue, in a measured, phased and strategic way, 
with attention on the Waterford/South East and Cork in the first instance.  There 
should be dedicated resources and personnel assigned to Naloxone roll out in each 
region. 
 
3.2  The phased roll out should be driven by the Chief Pharmacist and commence with an 
initial briefing/consultation with HSE personnel and relevant stakeholders in each 
location, e.g. professional bodies, GPs, pharmacists, clinical nurses and social care 
workers.  
 
3.3  One other region should be drawn in, based on the NDRDI4 data, over the next twelve 
months.    
 
3.4  There should be specific administrative support dedicated to the Naloxone roll out.   
 
 
 
 
 
 
 
 
 
                                                 
4 National Drug-Related Death Index, Health Research Board 
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Recommendation Four - Refining the Training  
 
4.1  The Naloxone Training should be continued, incorporating the learning from this 
evaluation.   
 
4.2  The training should be accredited by an appropriate body5.   
 
4.3  A training schedule should be prepared and disseminated prior to delivery of any 
further training.   
 
4.4  The scheduling of the Train the Trainer component should be such that participants 
have an opportunity to practise and apply their learning as soon as possible (ideally 
within three months) after receiving the training.    
 
4.5  Accredited CPR training, delivered by a qualified and accredited tutor(s), should be built 
into the training programme6.   
 
4.6  Opportunities for refresher training, peer support and reflective practice should be built 
into the suite of future training.   
 
4.7  Collaborative work with the National Family Support Network should continue so as to 
include family members in all future training and development events.  
 
4.8  There should be ongoing evaluation of all future training.   
 
4.9  Pre and post training evaluation forms should be modified to include participant profile 
data 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                 
5 This is already in train in consultation with the Pharmaceutical Society of Ireland. 
6 This is being introduced. 
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Recommendation Five – Briefing of Service Users  
 
5.1  Training/briefing of service users in the use of Naloxone should continue and be 
informed by the learning from this evaluation of the Demonstration.   
 
5.2  Training/briefing of service users should be monitored carefully.  Front line staff 
members who deliver the training/briefing should be supported to ensure quality and 
consistency.   
 
5.3  All front line workers should be trained and supported to work with their hard to reach 
clients. 
 
 
5.4  Specific attention should be paid to monitoring those service users who have been 
briefed and prescribed Naloxone.  This should include tracking their health, well-being 
and drug related behaviour over time, e.g. through replenishment records, repeat 
overdose incidents, etc.7     
 
Recommendation Six – Research, Tracking and Monitoring 
 
6.1  There should be continued research in Ireland in relation to Naloxone.  A central theme 
will be the monitoring of the effect of Naloxone in reducing the number of fatal 
overdoses.   
 
6.2  The research should be multi-disciplinary and overseen by the QAG with a particular 
emphasis on clinical governance.  Partnering with an academic establishment or 
research organisation will drive and support future research. 
 
6.3  There should be quarterly meta-analysis of the risk assessment forms (F2) and post 
incident forms (F5) to note any patterns in medical risk, drug related behaviour, 
frequency and features of overdose.  It is important that there be continued vigilance in 
full completion of these records by all those responsible, i.e. pharmacists, GPs and front 
line workers. 
 
6.4  The work that commenced during the Demonstration in cultivating the connections/ 
relationships with peers in other countries implementing Naloxone, e.g. Wales and 
Scotland, should continue.   
 
  
                                                 
7 Currently all those participating in the Naloxone programme have given their consent to the sharing of 
their data for monitoring purposes. 
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Chapter One 
Introduction 
1.1 Introduction 
This report provides an account of the external evaluation of the Naloxone Demonstration 
Project that was rolled out in Ireland by the Health Service Executive (HSE) during 2015. 
 
The HSE is committed to actions that serve to reduce the number of drug-related deaths and 
near-fatal drug poisonings. A key action set out in the Primary Care Division Operational Plan 
2015 was to “Implement a Naloxone Demonstration Project to assess and evaluate its suitability 
and impact (in line with National Drug Strategy Action 40).” 
 
1.2. Aims & Objectives of the Naloxone Demonstration Project 
The purpose of the Naloxone Demonstration Project was to test the feasibility of making 
Naloxone available for use by opioid users in order to prevent death from overdose.   
 
Naloxone is a medicine (an ‘opioid antidote’) commonly used by healthcare professionals and 
ambulance services to reverse the effects of an opioid overdose8 and bring the person back to 
consciousness.  Prenoxad ™ (1mg/ml injection) was made available under Summary of Product 
Characteristics (SmPC) agreed with the Department of Health.  It is injectable, administered via 
the parenteral route and formulated in a specific overdose pack. It has additional labelling to 
allow for lay administration. Each pre-filled syringe contains five doses of Naloxone.  The 
intention was that after a single individual use this would be reported in tune with agreed 
practice.  The pack would be then be discarded appropriately and the patient sent back to their 
agreed point of contact for replenishment.  
 
A central element of the Demonstration Project was the formal briefing of drug users and 
training of those close to them (e.g. service providers, front line workers and family members) 
in the use of Naloxone and in recognising and effectively managing overdose events.  
 
The Demonstration Project aimed to involve 600 people receiving take-home Naloxone within 
the current legislative framework.  The primary target population was drug users at risk of 
opioid overdose in the community and ex-prisoners on release.   
                                                 
8 Definition of Opioid Overdose: difficulty breathing, turning blue, lost consciousness, unable to be 
roused, collapsing occurring in conjunction with opioid use (opioids such as heroin, methadone, 
morphine, oxycodone, tramadol, fentanyl or codeine). 
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1.3 Budget 
The Demonstration Project was funded through the HSE National Social Inclusion Office. The 
final budget agreed was €62,500 to cover administration, design and delivery of training across 
the four demonstration sites, distribution of the Naloxone kits, recording and tracking of 
prescription, research and external evaluation 
 
1.4 Management & Governance 
The Project was led by Denis O’Driscoll, Chief Pharmacist, Addiction Services, HSE.  As Project 
Lead he was authorised to manage the Demonstration Project with responsibility for 
developing the project plan, implementing and monitoring the project schedule, financial 
oversight and performance monitoring.  All supplies of Naloxone were channelled through the 
Project Lead who was responsible for all procurement and replenishment of supply. 
 
The Naloxone Quality Advisory Group (QAG) was established to oversee the implementation 
of the project (see Appendix for membership).  
 
The objectives of the QAG were to: 
 
 Oversee planning and roll-out of a Naloxone Demonstration. 
 Advise on the evaluation of the pilot. 
 Make recommendations for next steps following the evaluation. 
 Publish findings in a peer reviewed journal. 
 Plan and oversee required proposal/action (e.g. legislative changes) to support legal 
provision of Naloxone to opioid users and their family members. 
 
1.5 Scope of the Evaluation  
This external evaluation was commissioned by the HSE to accompany the Demonstration 
Project, to document and report on the implementation.   
 
There were two elements to the evaluation: a process evaluation and an outcome evaluation.  
 
The aim of the process evaluation was to determine the nature and quality of the programme 
implemented by investigating:  
 
1. The implementation of the main elements of the programme.  
2. The nature and quality of the training sessions. 
3. Participants’ views of the programme as a whole. 
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The aim of the outcome evaluation was to investigate:  
 
1. Learning and other outcomes from the training sessions.  
2. Practical application of Naloxone in overdose situations.  
3. Practical application of other harm-reduction actions in overdose events. 
4. The effect of Naloxone in reducing the number of fatal overdoses. 
 
1.6 Evaluation Methodology 
The evaluation formally commenced in June 2015.   The field work was action research 
oriented, given the nature of the Demonstration Project, and was conducted between June 
and October 2015.   
 
The methodology included a blend of qualitative and quantitative research techniques in order 
to meet the terms of reference.  The principle component of the methodology was a classic 
stakeholder analysis designed to invite inclusive and voluntary input into the evaluation 
process across the full range of stakeholders.  This was purposefully intended to fit with the 
unfolding implementation across four different locations and in anticipation of potential 
variance across these sites. 
 
The following is a summary of the main elements in the methodology: 
 
 Desk Research: 
 A review of recent, relevant literature with a particular focus on noting the use of take-
home Naloxone in other jurisdictions, e.g. Scotland and Wales. 
 
 Review of all training records and resource materials developed and used during the 
Demonstration, e.g. training manuals, videos, resource packs, scheduling and 
administration documentation. 
 
 An open e-invitation was issued by the Chief Pharmacist to all stakeholders to 
contribute to the evaluation process by contacting the evaluation team directly and in 
confidence during the course of the Demonstration Project.  This was structured 
around the following e-questionnaires some of which were returned on line and others 
discussed during research visits and/or telephone interviews conducted by the 
evaluators: 
 
o E-questionnaire for completion by front line workers (6) 
o E-questionnaire for completion by managers of services (3) 
o E-questionnaire for completion by trainers (6) 
 
 Analysis of all secondary data relevant to the Project, e.g. 
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o SPSS analysis of pre and post training questionnaires (n=492), containing Opioid 
Overdose Knowledge Scale (OOKS) and Opioid Overdose Attitude Scale 
(OOAS)9 to gauge progression post training. 
o Prescriptions issued and replenished and related data (excel spread sheets from 
two of the pilot sites - Dublin and Limerick). 
o Incident Follow Up Reports (Form 5). 
 
Field Research: 
 Consultations and ongoing communication with the HSE Chief Pharmacist/Project 
Manager of the Demonstration Project.  The purpose of these consultations was to: 
 
o Track the Demonstration Project as it unfolded.  
o Access data on roll out of training including nature of the learning, quality, 
attendance, challenges arising, etc. 
o Access data on prescriptions issued and replenished, risk analyses conducted, 
service user assessment, etc. 
o Gain access to key stakeholders including trainers, HSE personnel, medical 
professionals, front line workers, family members, etc. 
o Note strengths and weaknesses of the process. 
 
 Consultations with the Quality Advisory Group (QAG).  The purpose of these 
consultations was to: 
 
o Gain their input into the evaluation from the outset (both individually and as a 
group). 
o Present an interim report in September 2015 for consideration and discussion 
(meeting to discuss this on 6th October 2015). 
o Become alert to challenges as the Demonstration Project unfolded. 
o Record drug related deaths. 
 
 Observation of training delivery at Merchants Quay Ireland (MQI) on 4th August 2015. 
 Research visits to a sample of four service providers10 for consultation with 
management and staff trained in the use of Naloxone.  
 
                                                 
9 This scale was developed and validated by Anna Williams, John Strang and John Marsden from the 
Addictions Department, Institute of Psychiatry and Psychology and Neuroscience, Kings College, 
London.  The psychometric properties were tested and published in:  Williams, AV, Strang, J & Marsden, 
J (2013).  Development of Opioid Overdose Knowledge (OOKS) and Attitude (OOAS) Scales for take 
home naloxone training evaluation.  Drug Alcohol Dependence.  132(1-2): 383-6.9 
 
10 Merchants Quay Ireland, Ana Liffey Drug Project (Midwest), Cedar House, Mc Garry House, Novas 
Initiatives, Limerick. 
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 Consultations with medical professionals (6) and relevant HSE senior personnel (7) 
working in social inclusion and substance misuse nationally and within the four 
demonstration sites. 
 Consultations with family members who attended Naloxone training sessions (4). 
 Case stories of Naloxone administration during the life time of the Demonstration 
Project (5 case stories). 
 
1.7 Structure of this Report 
Following this introduction, Chapter Two presents a review of the literature and sets the 
Demonstration Project in context.  Chapter Three describes the implementation of the Project 
and Chapter Four looks at early outcomes and impact.  Chapter Five draws conclusions and 
offers pointers to inform decision making in relation to further roll out of Naloxone and related 
supports.  
15
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Chapter Two 
Literature Review & Context 
 
This chapter sets out the salient points from a review of recent, relevant literature and policy 
documentation.  It places the Demonstration Project in context as one intervention in the suite 
of Ireland’s responses to the increase in drug related deaths. 
2.1 Drug-Related Overdoses 
Ireland has one of the highest drug overdose rates in Europe.  Data from the National Drugs 
Related Death Index (NRDI)11showed that in 2012 all ‘poisoning deaths’ related to drugs came 
to 350 (down from 384 in 2011).  Opioids alone accounted for 7%, analgesics which had an 
opioid compound was 5%, poly-substances including opioids (e.g. methadone, analgesics, 
heroin) was 40%. In total, opioid related deaths (ORDs) made up of single drug and poly-drug 
frequency was 220 (263 in 2011). The median age for all poisonings was 40 (it was lower for 
men at 38 and higher for women at 49).  This concurs with the international experience where 
most deaths occur in experienced drug users in their late 20s and early 30s rather than in 
inexperienced drug users.   The Irish age profile is a little higher and seems to reflect an ageing 
population on methadone treatment12.  Recent Irish data indicates that over two fifths (42%) of 
people who died of deaths where heroin (injecting or smoking) was implicated were not alone 
at the time they took the drug.  This suggests that there may have been an opportunity to 
prevent these deaths through the administration of Naloxone.13 
2.2 National Drugs Strategy 
The overall objective of the National Drugs Strategy (2009-2016) is to tackle the harm caused 
by misuse of drugs. The actions set out to achieve this centre on reduction in supply, 
prevention, treatment, rehabilitation and research. Action 40 relates specifically to the 
Naloxone Demonstration Project in that it refers to responding to drug related deaths through 
three specific actions.  The first action is the development of a National Overdose Prevention 
Strategy, which is in progress. The second is a coordinated response to the rise in deaths 
indirectly related to substance abuse.  The third action is a review of the regulatory framework 
in relation to prescribed drugs. 
 
                                                 
11 HRB, 2014, ‘Drug-related deaths and deaths among drug users in Ireland’, Dec 2014 
12 HSE Central Treatment List 
13 http://www.hrb.ie/uploads/tx_hrbpublications/NDRDI_web_update_2004-2013.pdf 
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2.3 NDRIC 
The National Drugs Rehabilitation Implementation Committee (NDRIC) was set up to oversee 
and monitor implementation of recommendations from the Report of the Working Group on 
Drug Rehabilitation (2007); to develop agreed protocols and Service Level Agreements (SLAs); 
to develop quality standards, building on existing standards; to oversee case management and 
care planning processes, and to identify core competencies and training needs and ensure 
these needs are met. 
NDRIC developed a framework for drug rehabilitation interventions (2010).  The framework 
arose out of recommendations made by the Working Group on Drugs Rehabilitation14.   
The NDRIC framework aims to assist service providers to plan and implement a range of 
approaches to provide an Integrated Care Pathway for former and current drug users. The 
framework recognises that drug users have many and varied needs, which may require a range 
of supports and interventions by different service providers.  
The research shows that well coordinated service provision eases client navigation through the 
system and strengthens the possibility of effective care and treatment.  Good coordination 
increases efficiency in gathering and managing client data and minimises any need for clients to 
provide the same information repeatedly to multiple organisations.  This generates an 
encouraging sense of positive movement and progression for clients as they encounter 
different services in the course of their treatment and care. 
NDRIC describes a Rehabilitation Pathway in the context of four tiers of service provision. The 
first tier includes interventions with a primary focus on psycho-social care and support, e.g., 
family support, training and employment support, education, access to accommodation and 
suitable housing support, etc.  The second tier centres on treatment related interventions, e.g. 
pharmacies, primary care, community-based services, specialist addiction services, etc.  The 
third tier comprises specialist treatment related interventions in prison, community and/or 
hospital settings.  The fourth tier is specialist dedicated inpatient or residential units and wards. 
The Naloxone Demonstration Project fits within all four tiers of service provision and Naloxone 
(as a lay administration) has potential to be particularly useful in tiers one and two. 
2.4 Naloxone 
Naloxone is a medicine recommended by the World Health Organisation for treatment in 
opioid overdose cases.  It acts by reversing the effects of opioid overdose within minutes. Its 
efficacy has been well proven internationally.   
Naloxone has been in use in Ireland in intravenous form in medical settings, for many years, by 
emergency services personnel and healthcare professionals. Intramuscular and nasal take home 
versions of the product have been introduced in other countries.   
 
 
                                                 
14 Report of the Working Group on Drugs Rehabilitation, May 2007, HSE 
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A national Naloxone Advisory Group (established to oversee the design, delivery and 
evaluation of an educational intervention for overdose prevention and Naloxone distribution 
by general practice trainees15) determined that the intervention of choice is the intranasal 
formulation (IN).  This formulation has yet to be authorised and licensed on the European 
market, recently an IN has been licensed for use in the USA (www.adaptpharma.com/press-
releases/ ). 
The version of Naloxone used in the demonstration project was an injectable prefilled syringe 
(Prenoxad™) containing five doses (0.4ml).   This product has additional labelling for lay 
administration in cases of emergency.  It is a prescription only product. 
Overall, the research suggests that Naloxone is suitable for precautionary carrying on their 
person by those who use opioids (e.g. heroin), are participating in opioid substitution therapy 
(e.g. methadone), leave prison with a history of opioid use and/or have previously used opioid 
drugs and a history of overdose. 
2.5 Application of Naloxone – International Findings 
The average annual number of drug-related deaths over the nine year period 2004-2011 was 
34616.    Opioid overdose accounted for over sixty percent of fatal overdoses in Ireland. 
Naloxone is an opioid antagonist that can temporarily reverse the effects of opioid overdose.  
This can provide a window of opportunity to prolong a life while waiting for emergency 
services to arrive and medically treat a person who has overdosed.  Naloxone can be 
administered intramuscularly, intravenously or by nasal spray.  The Demonstration Project used 
the intramuscular version of the product. 
Research by Wheeler17 concluded that providing Naloxone kits to laypersons has the potential 
to reduce death as a result of overdose, is safe to administer and cost effective. 
Naloxone has been available to counteract drug overdose in the USA for over two decades 
and in some EU countries (e.g. Italy) since the 1980s. It was introduced in Wales in 2009 and 
in 2011, Scotland was the first country to adopt take home Naloxone (THN) as a funded public 
health policy. Evaluations of both the Scottish18 and Welsh19 pilot projects were conducted.   
 
 
                                                 
15 ‘Development and process evaluation of an educational intervention for overdose prevention and 
naloxone distribution by general medical practice trainees’, Jan Kilmas, Mairead Egan, Helen Tobin, Neil 
Colman and Gerard Bury. BMC Medical Education (2015) 15:206 
16 NDRS 2012, HRB 2014 
17 Wheeler, E., et al, 2014, ‘opioid Overdose Prevention Programs Providing Naloxone to Laypersons – 
United States 2014’, Centers for Disease Control and Prevention. 
18 Watt, Glenys, et al, Research Findings No. 51/2014.  Service Evaluation of Scotland’s National Take 
Home Naloxone Programme. 
19 Bennett, T., Holloway, K., 2011, ‘Evaluation of the Take Home Naloxone Demonstration Project’, 
Ymchwil Gymdeithasol Social Research No.13 
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The combined learning from these evaluations is summarised below. 
 A clear management and reporting structure is an important success determinant for 
the roll out of Naloxone as a public health measure in any location. For example, in 
Scotland a national co-ordinator was appointed in a dedicated capacity to oversee local 
management of the project. 
 Better results were achieved when participants participated in all the components of 
the training, e.g. recognising and managing an overdose episode, role play/practice in 
administration of Naloxone, CPR, simulation etc.  This concurs with the findings of 
recent research conducted in Ireland by Kilmas et al and reported in the BioMed 
Central20.  This research found that simulation was the most effective training delivery 
method. 
 Incremental and phased roll-out of the programme enhanced adjustment, acceptance 
and higher uptake. 
 Including prisons as a setting for Naloxone training and administration works well.  The 
research shows that as many as half of drug overdoses occur with ex-prisoners21. 
However, because prisoners on release could possibly obtain their Naloxone twice, i.e. 
when leaving prison and when in the community, this must be carefully monitored as it 
has potential to distort the data. 
 The most effective way to deliver Naloxone training to service users is through one-to-
one briefings and through outreach rather than in groups. 
 The research alerts us to the importance of time and process in generating awareness 
and understanding of the value and potential of Naloxone. The training performs an 
important function in this regard.  As more people participate in the training and more 
kits are distributed people’s understanding and appreciation of Naloxone and its use is 
growing.  Leading by example takes time and yet works well with a critical mass of 
people paving the way for others.   
 Trainers in community sites in Wales reported better learning outcomes and benefits 
than those in prison sites. 
 The main benefits cited, arising from the Naloxone training, were improved knowledge 
and understanding of opioid overdose, improved ability to recognise the signs of an 
opioid overdose and clearer understanding of the correct actions to take in an 
overdose situation. Other outcomes included improved skills to successfully conduct 
CPR and place a person in the recovery position correctly and to administer Naloxone.   
                                                 
20 ‘Development and process evaluation of an educational intervention for overdose prevention and 
naloxone distribution by general medical practice trainees’, Jan Kilmas, Mairead Egan, Helen Tobin, Neil 
Colman and Gerard Bury. BMC Medical Education (2015) 15:206 
21 Zander, et al, 2005, ‘National Investigation into Drug Related Deaths in Scotland, 
www.scotland,gov.uk/Publications/2005/08/03161745/17507   
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 Participants expressed greater confidence and willingness to administer Naloxone.  
Participants who were drug users were more likely, after attending the Naloxone 
training, to have increased contact with the relevant support agencies and to want to 
receive testing for Hepatitis C and HIV.  There were also reported incidents of drug 
users re-evaluating their heroin use and the harms relating to it. 
 The main reasons for re-ordering Naloxone kits were kits being lost or mislaid, use of 
the kit on self or another (more usually the latter), and kits passing their expiry date.  In 
a small percentage of cases, kits were confiscated by the authorities. 
 The results from the pilot project in Scotland show that around 5% of the Naloxone kits 
distributed were used to assist in an overdose incident.  The figure for Wales was 
somewhat higher at 7%.  Subsequent national monitoring data for Scotland suggests at 
least 6% and more likely 9% usage. 
 Data from Wales indicates that of 22 reported cases of overdose where Naloxone was 
administered, 21 survived and one did not (96% survival rate). Of note are the 
additional seven people who experienced an overdose episode but declined assistance.  
 The survival rate showed no measurable difference in outcomes when compared with 
the control group.  The common factor in both groups was that there was someone 
there able to help and support.  It is likely that this capable human presence increases 
the likelihood of survival and this warrants further monitoring and research over time 
to confirm.  The number of overdose events that were not witnessed and went on to 
be fatal or recoverable was unknown.   Case studies of deaths where Naloxone was 
not administered showed that the majority were alone at the time of overdose.  
 Those who had received training in the use of Naloxone were more likely to use other 
harm reduction actions such as CPR, placing the person into the recovery position 
correctly, calling for an ambulance and calling the police. Having a capable individual 
present who can take effective action is critical to survival. 
 In Scotland, re-supply due to loss of the product was quite common (44% of 
community re-supply). 
 Sufficient supply and availability of Naloxone is a key success determinant.  Bird el al 
(2014)22 recommend that nations gauge the sufficiency of provision against a target of 
twenty times their (most recent past) mean annual number of opioid related deaths, 
with minimum provision being at least nine times this number. Applied in an Irish 
context this means annual supply of between 2,030 and 4,500 would be required.  
 
                                                 
22 Bird, S.M., Parmar, M., Strang, J., ‘Take-home naloxone to prevent fatalities from opiate-overdose: 
Protocol for Scotland’s public health policy evaluation, and a new measure to assess impact’, Drugs, 
Education, Prevention and Policy, 2015, 22 (1), p.66-76 
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However, based on the experience of Glasgow23, where there is a comparable addiction 
population and experience of the Irish demonstration project to date, the Chief Pharmacist 
estimates that annual supply is more likely to be around 600 per annum.  
 It is generally recognised that General Practitioners are important stakeholders in the 
successful delivery of Naloxone.  Some medical professionals express reservations 
about the use of Naloxone by laypersons.  While this is understandable, the research to 
date indicates that the risks of Naloxone misuse have been reported as very low24. 
 The engagement of GPs and their acceptance and championing of Naloxone is an 
important determinant in the successful reach of any programme.  A study in Scotland 
by Matheson et al (2014)25 highlights a number of challenges to positive participation 
by GPs in any such programme.  These challenges included: 
o Substance misuse is not generally considered part of the expected everyday body 
of work for GPs. 
o Challenge for GPs to find time to attend training in general. 
o Concerns about drug user behaviour and attitudes. Some expressed concern that 
the availability of Naloxone might influence negative changes in behaviour, e.g. 
those who were previously fearful of using heroin might start using if Naloxone is 
available or existing heroin users might increase their dosage as a result of the 
availability of Naloxone (there is no evidence to date of this negative effect).   
o Perception of drug users where drug use is viewed as more of a criminal matter 
than a health matter.  
o GPs see their primary role as one of prescribing, and not of briefing or training (e.g. 
in the use of Naloxone) with most feeling this work is more suited to nurses, key 
workers, addiction counsellors, etc.   
o The research indicates that providing a strong clinical evidence-base for the use of 
Naloxone will encourage GP participation.  Payment is also a factor.  Most believe 
that the preferred person to deliver Naloxone briefings to patients is the front line 
worker with most contact with the patient.  This is rarely a GP. 
Research26 in the US found that organisations providing syringe exchanges and harm reduction 
programmes for injecting drug users were early adopters of opioid overdose prevention 
                                                 
23 The number of kits supplied in Glasgow was no more than 599 in any given year.  
24 Ashworth, A. J. & Kidd, A. 2001, ‘Take Home Naloxone for Opioid Addicts.  Apparent Advantages may 
be balanced by Hidden Harms.’ British Medical Journal, 323, 935. 
25 Matheson, C., et al, 2014, ‘Reducing drug-related deaths: a pre-implementation assessment of 
knowledge, barriers and enablers for naloxone distribution through general practice’, BMC Family Practice 
2014, 15 (12). 
26 Doe-Simkins, M., et al, 2009, ‘Saved by the nose: bystander administered intranasal naloxone 
hydrochloride for opioid overdose’, American Journal of Public Health, 99, p.788-91; Enteen, L., et al 
2010, ‘Overdose prevention and naloxone prescription for opiate users in San Francisco’, Journal of 
Urban Health, 8, p.931-41 
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programmes, including the use of Naloxone.  This suggests that there is a cultural 
predisposition and preparedness to embrace such measures. 
A scan of evaluations of the use of Naloxone indicates high survival rates where it is 
administered.  There is little comparative data available about outcomes that occur without the 
use of Naloxone. A study in Chicago indicated that heroin related overdose deaths in Cook 
County fell by 20% in the year after the introduction of Naloxone and 10% in the subsequent 
two years27.  Research by Bird et al28 found that 19 out of 20 cases of accidental overdose will 
be resolved irrespective of whether or not Naloxone is administered. 
Source Deaths prevented : lives lost 
when Naloxone used 
Deaths prevented : 
lives lost when 
Naloxone not used 
USA Los Angeles (Wagner et al 
2010) 
26:4 
(87%)29 
Na 
USA San Francisco (Seal 2005) 15:0 
(100%) 
Na 
USA New York (Galea 2006) 10: 0 
(100%) 
Na 
USA Baltimore (Tobin 2009) 19: 0 
(100%) 
Na 
Wales (Bennett 2011) 21:1 
(96%) 
38:1 
 
Scotland Glasgow (Shaw 2008) 10:1 
(95%) 
Na 
Scotland Lananhshire (McCauley 
2010) 
2:1 
(67%) 
Na 
U.K. South east/south west, 
midland/.north (Stray 2008) 
12:0 
(100%) 
6:1 
 
Ireland demonstration project 5:0 within a five month 
period30  
(100%) 
Na 
 
 
 
 
                                                 
27 Maxwell, et al, 2006, ‘Prescribing Naloxone to Actively Injecting Heroin Users: A Program to Reduce 
Heroin Overdose Deaths’, The Haworth Press. 
28 http://informahealthcare.com/dep ISSN: 0968-7637 (print), 1465-3370 (electronic) 
Drugs Educ Prev Pol, 2014 Early Online: 1–11 
Take-home naloxone to prevent fatalities from opiate-overdose: Protocol for Scotland’s public health 
policy evaluation, and a new measure to assess impact. Sheila M. Bird, Mahesh K. B. Parmar, and 
Professor John Strang. 
29 A total of 35 overdose events were recorded but the outcomes in respect of 5 were unknown. 
30 There were three more reported administrations of Naloxone in the period after this evaluation was 
completed, i.e. November – December 2015. 
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2.6 Impact of Naloxone 
A survey by Wheeler et al (2014) of 140 mangers of organisations in the US known to provide 
Naloxone kits to lay persons found that from 1996 to June 2014 surveyed organisations had 
provided Naloxone kits to 152,283 laypersons and had received reports of 26,463 overdose 
reversals (17%)31. 
The European Monitoring Centre for Drugs and Drug Addiction (2015)32 completed a meta-
analysis of available studies on take-home Naloxone.  The results found that educational and 
training interventions complemented by take-home Naloxone affected a decrease in overdose 
related deaths and improved knowledge and attitudes about the correct use of Naloxone and 
the management of witnessed overdoses amongst opioid-dependent patients and their peers.  
2.7 Cost effectiveness 
Research, in the United States, by Coffin and Sullivan (2013)33 into the cost effectiveness of 
lay distribution of Naloxone found that it was cost-effective in every scenario examined.  It 
was found to be cost-saving when it resulted in fewer overdoses and/or medical emergency 
activations.  Coffin et al estimated that 6% of national deaths due to overdose would be 
prevented by distributing Naloxone and that one death would be prevented for every 227 kits 
distributed.   
2.8 Training & Briefing in the Use of Naloxone 
There are a range of methods to disseminate training and briefing in the use of Naloxone.  
The methods include: 
 a cascade method whereby a core group of healthcare professionals (or other 
professionals) are trained to train other healthcare professionals, who in turn train front 
line workers to brief drug users;  
 direct provision of training to drug users and their families;  
 direct provision of training to mixed groups of professionals who in turn train drug 
users, and  
 direct provision of training mixed groups of professionals and drug users.  
The most effective single method for disseminating training in the use of Naloxone has not yet 
been identified34.  The challenges noted in relation to achieving effectiveness with the cascade 
methods relate to the large size of caseloads and people, while well intentioned, are too busy 
to train/brief others.   
                                                 
31 Wheeler, E., et al, 2014, ‘Opioid Overdose Prevention Programs Providing Naloxone to Laypersons – 
United States’, Morbidity and Mortality Weekly Report 
32 EMCDDA, 2015, ‘Preventing fatal overdoses: a systematic review of the effectiveness of take-home 
naloxone’, Luxembourg. 
33 Coffin, P., Sullivan, S., 2013, ‘Cost-effectiveness of Distributing Naloxone to Heroin Users for Lay 
Overdose Reversal’, Annals of Internal Medicine, 158, p.1-9. 
34 Mayet et al, 2011, ‘Impact of training for healthcare professionals on how to manage an opioid 
overdose with naloxone: Effective dissemination is challenging’, International Journal of Drug Policy, 22, 
p.9-15 
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The results of this research for the Irish Demonstration Project also point to challenges in 
terms of scheduling training/briefing sessions, maximising attendance, achieving consistency of 
input across locations and groups, post course evaluation and support. 
The nature, quality and extent of training is also important including the delivery methods (e.g. 
face to face tutoring, simulation/practice/role plays and/or DVD) use of resource materials and 
whether the learning is group based or one to one.  A study of family members and carers, 
many of whom witness overdoses35, showed that group-based training resulted in better 
outcomes on the Overdose Knowledge scale and the Overdose Attitudes scale than those who 
received information only by way of a booklet with DVD enclosed.  The group based learning 
environment offered information using oral presentation (tutor) and DVDs combined with 
practice in the correct actions to take in an overdose event.  This includes practice in 
administering Naloxone.  
The Scottish evaluation found that one-to-one training in a community setting was more 
effective than group training but that group training could be effective in a prison setting36. 
Other non-injectable forms of delivering Naloxone have been developed.  For example, in April 
2014 the FDA approved a new hand-held auto-injector specifically designed for family 
members and caregivers. Furthermore, there are two clinical trials currently underway in 
Denmark and Norway examining the use of injectable Naloxone with the use of a mucosal 
atomizer device (MAD).  This is attached to the injection and sprayed into the nostrils.   
2.9 Legislative Context 
Under existing legislation, Naloxone is licensed in Ireland in injectable form for provision to a 
patient through a prescription from a medical doctor.   
There was significant preparation and ground work completed in advance of the 
Demonstration.  The following is a summary of the steps that paved the way for the Naloxone 
Demonstration Project in Ireland:  
 
 During a meeting between the HSE and Department of Health in May 2013 it was 
agreed that the Demonstration Project would operate within the confines of existing 
legislation.  A number of possible locations were considered.   
 
 
 
 
 
 
                                                 
35 Strang et al, 2008, ‘Family carers and the prevention of heroin overdose deaths. Unmet training need 
and overlooked intervention opportunity of resuscitation training and supply of naloxone’, Drugs: 
education, prevention and policy 15 (2), p.211-218 
36 Watt, G. et al, 2014, ‘Service Evaluation of Scotland’s National Take-Home Naloxone Programme’, 
Scottish Government Social Research. 
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 There was detailed discussion between the Chief Pharmacist, the HSE and the 
Department of Health about the product and which version of Naloxone was 
appropriate and legal for use in Ireland. The Chief Pharmacist expressed a preference 
for an intranasal naloxone (INN) formulated product.  However, as there was no 
authorised INN product available at the time of the Demonstration the next best 
product of choice was the prefilled fives dose product which was authorised in a 
member state (Prenoxad ™).  This had been used in other national naloxone 
programmes.  This product was only licensed to be used via the intramuscular route. 
The programme is awaiting clinical trial results, mentioned above, on the use of the 
mucosal atomizer device (MAD) with the Naloxone syringe. 
 
 It was agreed that prison settings would be included and a Doctor would issue a 
prescription which would be dispensed within the prison and sealed and handed over 
to the individual on release.   
 
 The community settings for the project would operate through the clinics where the 
clinic Doctor would issue a prescription and have it supplied on site by the Doctor.   
 
 The Gardai were asked to participate in the Demonstration Project and were invited to 
attend training.   
 
 The Naloxone formulation, as a pre-filled syringe (Prenoxad ™), was made available to 
the Irish market on the basis that within the current SmPC (Summary of Product 
Characteristics) it contains additional labelling for the administration of the product by 
caregivers, front line workers, family members, drug users, addiction clinic staff, etc.  
These discussions took place in collaboration with the Department of Health, HSE and 
HPRA.  Dialogue is on-going, between HPRA and the manufacturer, about the 
formulation’s authorisation and licensing status in Ireland. 
 
 It was agreed that safety concerns about accidental contact with Naloxone syringes 
and safe working with sharps would be addressed through the training. 
 
 The Chief Pharmacist maintains a register of all those prescribed with Naloxone and is 
implementing a system to remove out of date Naloxone syringes from circulation. Each 
person will be contacted six months in advance of the noted expiry date to alert them 
of the need to apply for a replacement. 
 
 Consideration of the types of locations and health professionals that could be 
permitted to store, supply and administer stocks of Naloxone in order to comply with 
existing strict rules for the chain of supply and record keeping of prescriptions. 
 In order to address safety concerns regarding regression into respiratory depression 
the training strictly emphasises the importance of calling for an ambulance. 
 The training addresses safety concerns about the competence and coherence of drug-
users to administer Naloxone to a person experiencing an overdose.  
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 Consideration of cost. A budgetary impact assessment of the cost of Naloxone for the 
Demonstration Project was conducted37. 
 
2.10 Summary of Chapter Two 
Opioid use is a significant factor in drug-related deaths in Ireland. Naloxone is a medicine that 
acts by reversing the effects of opioid overdose within minutes. Its efficacy has been proven 
internationally.  International experience indicates a high level of success in terms of survival 
rates when Naloxone is administered in an overdose situation.  Another factor that can affect a 
positive outcome is the presence of a capable person able to take appropriate action in an 
overdose situation, e.g. remain calm, qualified in first aid and trained in CPR.   
 
Good quality comprehensive training is an important component of any Naloxone programme.  
Other important and related success determinants include GP, pharmacist and service provider 
(e.g. outreach service, homeless services, needle exchanges) commitment and participation and 
sufficient reach of the product to those in need within a population.  
 
Under current legislation in Ireland, Naloxone is licensed as an injectable formulation for 
provision to a patient through a prescription from a medical doctor.  The next chapter explores 
the implementation of the Naloxone Demonstration Project in Ireland during 2015. 
  
                                                 
37 Midway through this process the manufacturer repackaged the product and increased the price 
(npr.org/sections/health-stats/2015/09/10/439219409/naloxone-price-soars-key-weapon) (NB 
associated with the USA did not affect us but when Martindale repackage to an overdose kit Prenoxad 
™ increased from 5  to 25 euro) 
26
Evaluaon of the HSE Naloxone Demonstraon Project
27 | P a g e  
 
Chapter Three 
The Naloxone Demonstration Project Implementation 
The Naloxone Demonstration Project commenced in February 2015 after two years of 
preparatory work.  This chapter details the implementation of the Naloxone Demonstration 
Project during 2015.  The ground work that preceded and paved the way for the Project is 
described.  This is followed by an overview of the programme roll out across the four selected 
locations.  The challenges encountered during the implementation are noted. 
 
This chapter is based on the analysis of secondary data and the analysis of stakeholder 
consultations and site visits completed as part of the evaluation methodology.   
 
3.1 Milestones in the Demonstration Project 
The following is a summary of the developmental stages and milestones for the Naloxone 
Demonstration Project. 
  
The high level milestones for the project were as follows:   
 
 Meetings, preparation and promotion of the HSE intention to drive a Naloxone 
Demonstration Project in Ireland (October 2014 – January 2015). 
 Consultation with key stakeholders within the Department of Health, Health Products 
Regulatory Authority (HPRA), National Family Support Network (NFSN), voluntary 
support network, Irish Prison Service (IPS), Ana Liffey Drug Project (ALDP), Merchants 
Quay Ireland (MQI), National Drug Rehabilitation Implementation Committee (NDRIC), 
SafetyNet, Primary Care, Pre-Hospital Emergency Care Committee (PHECC) and the 
HSE Addiction Services. 
 Design and preparation of training schedule and resource materials.  Requested 
involvement of service users groups, SURF (Service Users Regional Forum) and UISCE 
(Union for Improved Services, Communication and Education38) 
 Completed design of half day training programme for testing during the Demonstration 
Project. 
 Agreement of external evaluation tendering and procurement process with the 
National Social Inclusion Office.  Issuing of invitation to tender for the evaluation 
process (early 2015). 
 Appointment of Eustace Patterson Ltd as the external evaluation team to accompany 
the Demonstration Project (May 2015). 
 Meetings of the Quality Advisory Group to oversee proposed train the trainer modules 
(January – February 2015). 
 Clarification with the manufacturer regarding multiple dose product and possible use of 
a disappearing needle (February 2015). 
                                                 
38 Drug Users Forum based in Dublin North Inner City 
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 Decision on the proposed locations for the Demonstration based on data from National 
Drug-Related Death Index Committee (NDRDIC), the Health Research Board (HRB), 
National Ambulance Service and Dublin Fire Brigade Ambulance Data.   
 Consideration given to the capacity of organisations to fulfil the criteria of rolling out 
training, availability of prescribers and also access to the more difficult and chaotic 
client (February 2015). 
 Importation of the product Prenoxad ™ via the Exemption Medicinal Product ( EMP) 
route as discussed with Department of Health and HPRA (February 2015). 
 First train the trainer programme delivered in the South East (Waterford 24th/25th 
February 2015). 
 Development of online site with www.drugs.ie to facilitate the training including online 
videos and literature. 
 Train the trainer programme delivered in Dublin (March 2015). 
 Formal launch of the Demonstration Project by the Minister for Health (21st May 
2015). 
 Roll out of training on site at proposed Demonstration locations39, e.g. Dublin, Cork, 
Limerick and Waterford (March – September 2015). 
 Evaluation initiation meeting with HSE Social Inclusion Office (11th June 2015). 
 Evaluation field work commences in June 2015 and runs through until the end of 
October 2015, including review and analysis of all secondary data, issuing of e-
questionnaires to stakeholders and site visits to five locations. 
 Dissemination of the evaluation tools for prescribing, dispensing and administration of 
Naloxone (May 2015). 
 Lead HSE Trainer successfully achieved recognised qualification as a fully accredited 
CPR Tutor/Community Responder to enhance the training in response to feedback. 
 Participation of the Naloxone Demonstration Project in International Overdose 
Awareness Day August 31st 2015 (www.ioad.com). 
 Interim Evaluation Report of the Demonstration Project presented to the Quality 
Advisory Group (October 2015). 
 Targeted training continues with delivery to specific groups, e.g. registrars (September 
– December 2015). 
 Discussions about possible inclusion of FDA approved nasal formulation of Naloxone 
deferred until the product is authorised (October 2015). 
 Demonstration Project formally completed (December 2015). 
 
  
                                                 
39 open access for all services regardless of Prenoxad ™ availability to them on site 
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3.2 Demonstration Project Locations 
Four locations were selected for the Demonstration Project - Dublin, Waterford/South East, 
Limerick and Cork.  The Train the Trainer programme was delivered and representatives from 
each location attended. 
 
The rollout progressed steadily in Dublin and Limerick and moved more slowly in Cork and 
Waterford.  The factors that supported the speed of rollout in a location included:  
 
 Prior awareness of and engagement with the Project. 
 Local champions of the Project (including GPs, HSE management and service providers) 
already in situ and energised to follow through and support practicalities of 
implementation. 
 Belief in Naloxone and the potential of the Project to make a difference, e.g. prevent 
deaths, support family members, fit successfully within harm minimisation work. 
 Proximity to the Project leadership, including involvement/representation in the QAG.  
 Practicalities including clear communication of the process and referral pathways, 
strong and clear links to GPs, clear prescribing systems, etc. 
 Acceptance, willingness and availability of GPs locally to engage with the project, 
promote and prescribe Naloxone. 
 Support from the National Family Support Network (NFSN) and its membership on the 
ground locally. 
 
3.3 Accessing Naloxone –Pathways 
There was a number of ways in which a service user could access Naloxone during the 
Demonstration Project.  These pathways are summarised in the figure overleaf.   
 
The common crucial elements across the pathways are the briefing of the service user about 
Naloxone and the role of the GP in medical assessment and prescribing of Naloxone. The 
briefing about Naloxone may occur one to one or in a group and with or without the support 
of a video learning accompaniment.  The briefing must be conducted by a trained person 
(usually a front line worker in a service providing organisation) in tune with the specifics 
outlined in the Naloxone and Overdose Training Resource Pack.  
 
The first access route is where a service user is working with a key worker/outreach worker in 
a service (e.g. a homeless support organisation).  The key worker (who has been trained in the 
use of Naloxone and briefing of others) conducts a risk assessment and briefs the service user 
about Naloxone.  The service user is then referred to the GP (attached to the service) who 
conducts an assessment and prescribes the product to the service user reiterating the main 
points from the Naloxone training.  These briefings/meetings may occur on the same day or 
across a number of sittings. 
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3.4 Naloxone Training Model 
The design of the Naloxone training was led by the Chief Pharmacist (Denis O’ Driscoll) and 
the National Liaison Pharmacy Worker (Tim Bingham) with initial and ongoing consultation with 
a wide range of stakeholders including the QAG.  In the spirit of inclusion, a multi-disciplinary, 
multi-agency approach was adopted from the outset.   
 
The overall aim of the training is to cover overdose prevention and the role Naloxone plays 
and its application in overdose situations. 
 
The Demonstration Project employed a cascade methodology to disseminate the training 
across the four demonstration locations40. This methodology commenced with selecting and 
training a group of individuals (31) to participate in the Train the Trainer programme.  The next 
step was to cascade all further training/briefing through these Trainers on location in the 
system across all four Demonstration sites.  The intention was that this group of Trainers were 
qualified, prepared and on hand to deliver the training locally and/or in response to needs 
arising. 
 
The second layer of the cascade model focused on delivering the training to a multi-
disciplinary, multi-agency audience.  The advantage of this approach ensured a broad base of 
services and professions participated in the training (e.g. pharmacists, GPs, nurses, frontline 
workers from a range of service providers, etc.).  This included family members (relatives of 
those at risk of overdose) who comprised an estimated 16% of those trained.  As of the end of 
August 2015, 492 people had received this training with more groups trained subsequently. 
 
The inclusive approach to training delivery in the early stages of the Demonstration limited 
opportunity to tailor the training to specific cohorts, e.g. GPs, senior nurses, prison officers, 
registrars, etc.  This was addressed later in the timeline through the delivery of training to very 
specific professional groupings, e.g. registrars and pharmacists.   
 
The training is specific and yet versatile for adaption for bespoke groupings. The National 
Family Support Network made progress in this regard by tailoring (expanding) the training to 
meet the needs of family members.  This bespoke training includes time spent on concerns 
about family members who are addicted to illicit drugs, coping with a family member who is 
vulnerable to overdose and the stress that this can cause within families.  This broadens out 
the training experience for family members in a positive way all the while recognising that a 
family member cannot be prescribed Naloxone to hold on behalf of their relative who is using 
drugs and vulnerable to overdose. 
 
 
 
 
                                                 
40 Mayet et al International Drugs Policy 2011, Impact for training health professionals 
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The learning from the evaluation tells us that a more specific and targeted approach to the 
delivery of the training from the outset would have facilitated tailored training for certain 
cohorts.  It would also have supported more precise sequencing and timing of the training to 
coincide with the available supply of Naloxone, confirmed access to a prescribing GP, 
general housekeeping (e.g. lap tops and video equipment to show the Naloxone 
training video) and organisational readiness, e.g. preparedness of organisations to 
incorporate Naloxone into their suite of service provision. 
 
3.5 Content of Training  
The Demonstration Project provided an opportunity to develop a robust Naloxone and 
Overdose training programme with a full suite of accompanying resource materials.  The 
content was informed by comprehensive prior research driven by the Project lead and 
consideration of the learning and good practice emerging from similar projects elsewhere. 
 
During the time frame of the Demonstration Project, a full set of training materials was 
designed, tested and refined.  This means that the first round of training sessions were test 
runs and all participated in the spirit of this learning.  The timing, the process, the content and 
delivery methods were all under scrutiny and feedback was sought from all stakeholders.  All 
aspects were refined over the life time of the Project in tune with this feedback. 
 
A central objective of the training was to develop and strengthen the awareness of frontline 
workers in all aspects of overdose.  This covered overdose risk factors, observable signs of 
overdose, what Naloxone is and how to administer it and what to do in an overdose situation.  
Full participation in the training was a prerequisite for frontline workers seeking to access the 
Naloxone and Overdose Frontline Workers Pack for use on location in their service.  This pack 
includes a training manual and related resource materials for use by frontline workers with 
service users in conjunction with four videos available on www.drugs.ie/naloxone.   
 
The manual covers overdose risks, what Naloxone can and cannot do, where to keep 
Naloxone, how to identify an opioid overdose, calling an ambulance, procedures for obtaining 
resupplies of Naloxone, what to do in the event of needle-stick injury and steps to take in 
responding to an overdose. 
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The manual contains five forms: 
F1:  Checklist of learning which must be completed by each frontline worker in 
respect of each service user they have trained. 
F2:  Opioid risk assessment form where an assessment of the service user is carried 
out by a frontline worker and is reviewed by a GP. 
F3:  Naloxone Demonstration Project Data Recording: Use & Supply form to be 
completed by GPs. 
F4:  Naloxone Demonstration Project Supply Consent to Share Information for 
Evaluation Purposes form to be completed by the frontline worker and GP. 
F5:  Incident Report Follow-up Form to be completed by a frontline worker and GP 
when an overdose is reported 
 
3.6 Data Management and Collection Systems and Completion of Forms 
A project of the size, purpose and impetus of the Demonstration Project requires significant 
resources.  The range of administrative supports necessary to manage and track a project of 
this nature includes training design and production of resource materials, logistics, event 
management, scheduling/time tabling of training events, monitoring and evaluating pre and 
post training and responding to issues as they arise.  Given the nature of the Demonstration it 
was also necessary to have sturdy administration systems and procedures around 
procurement, ordering and monitoring stock, prescribing, recording prescriptions, monitoring 
replenishment of supplies and tracking usage.   
 
During the Demonstration significant inroads were made in setting up systems to manage and 
track the work.  These include excel spread sheets for recording and tracking prescriptions, the 
use of Opioid Overdose Knowledge Scale (OOKS) and Opioid Overdose Attitude Scale (OOAS) 
to evaluate training and the suite of forms for recording critical incidents (F1 to 5 mentioned 
above).  Compliance with completing and returning these forms is crucial from a clinical 
governance stance.  It is also valuable data for research purposes and longitudinal analysis of 
the effect of Naloxone in reducing in reducing the number of fatal overdoses. 
 
The results of the evaluation show that there was significant underestimation of the work load 
and precision required to accomplish the full extent of the administration necessary for the 
project.  This warrants consideration into the next phase. 
 
3.7 Demonstration Project Implementation 
The analysis of the stakeholder consultations conducted during the evaluation draws attention 
to aspects of the Demonstration Project that worked well.  The results also highlight the 
lessons learnt and the challenges to prepare for into the next phase of the Project.   
 
The results are presented in the following four sections.  The intention is to inform future 
decision making in relation to Naloxone and possibilities beyond the Demonstration Project. 
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3.7.1. Stakeholder Involvement 
The Demonstration Project was a test run with a purpose.  It was, from the outset, heralded as 
an opportunity to learn about Naloxone and how to train the relevant stakeholders so that 
they are aware of its potential, its merits and limitations and how best to use it in appropriate, 
safe and life affirming ways.   
 
Stakeholder involvement was deemed an important success determinant from the outset.  The 
stakeholders include front line workers, family members, HSE management, medical and 
pharmaceutical professionals, paramedics, psychologists, Gardai, ambulance and social care 
workers and all the relevant professional bodies associated with the aforementioned. 
 
The results of the evaluation draw attention to what worked well in relation to activating and 
encouraging good involvement by the full range of stakeholders.   
 
Aspects of stakeholder involvement that worked well: 
 Open and inclusive approach and communication from the outset. 
 Partnership working between community and voluntary sector and HSE. 
 Communication, network and raising awareness of Naloxone within NDRIC and social 
care and community networks. 
 Inclusion of family members and the National Family Support Network. 
 Openness to learning and constructive criticism in the spirit of learning and continuous 
improvement. 
 
Aspects of stakeholder involvement that require attention: 
 Slow down the consultation process and adopt a more measured and strategic 
approach to consultation post Demonstration. 
 Continue to draw in the full suite of stakeholders, especially those who doubt the 
Project.  This worked well at the commencement of the demonstration and is worth 
continuing as open conversation and thought sharing will bring forward the quality of 
the product and the process. 
 Strengthen the presence and involvement of service user networks and organisations 
within the communication about Naloxone. 
 Acknowledge that some organisations and/or stakeholder groups are more cautious 
with respect to delivery of new programmes and need time to assess potential impact 
on their current service delivery.  0010.This means that they need time for internal 
review and preparation prior to commencement. 
 Invest more time in consultation pre implementation through formal and structured 
consultation with specific groups, e.g. service users, family members, GPs, etc.  
 Activate a centre point of communication to manage ongoing consultation, briefings 
and PR during implementation. 
 Strengthen communication with and support for the small cohort of trainers so that 
they are clear in their role as champions of the Project and confident in their capacity 
to deliver training locally.  This could be achieved through regular check (telephone or 
meeting) in with trainers. 
 Broaden the membership of the QAG to include more regional representation and 
widen clinical presence to include advocates and opponents of Naloxone. 
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3.7.2. Governance 
The Demonstration Project, as any project, required good governance at a number of levels.  
 
The results of the evaluation draw attention to what worked well in relation to governance 
with a particular emphasis on clinical, ethical and financial governance. 
 
Aspects of governance that worked well: 
 
 One single point of contact and leadership for the Demonstration – this conveyed a 
drive and positive energy that characterised and carried the Project from the outset. 
 The composition, presence and work of the Quality Advisory Group which comprised 
of a mix of community and voluntary organisations, service providers, the Health 
Service Executive (HSE), National Family Support Network (NFSN) and health 
professionals. 
 Access to expert clinical advice and goodwill in terms of advice and guidance, e.g. 
pharmacists, medical practitioners and addiction specialists. 
 Drawing on the experience and wisdom of programme leaders and clinicians in the UK 
and Scotland for advice and guidance prior to and during implementation. 
 
Aspects of governance that require attention: 
 
 Clarify and strengthen the terms of reference for the QAG and broaden its 
membership to formally include decision making/influencing clinical representation and 
HSE regional management and clinical representation (e.g. from the four locations and 
beyond).  This has happened informally to date, through consultation with clinical 
experts in each of the regions and the Addiction Services within the HSE. 
 Share the responsibility for management and promotion beyond one individual (the 
Chief Pharmacist) and into the regions. 
 Set out stronger and clearer communication and reporting channels and lines of 
responsibility for governance of addiction services within the HSE and across the four 
locations. 
 Achieve evenness in the awareness and commitment across the HSE locations and 
work through any doubt and resistance by HSE management, healthcare staff and 
health professionals.  
 Seek appropriate, workable and practical ways to embed Naloxone within addiction 
clinical governance41.  
 Resource the administration of the Project to ensure continuity and effectiveness of 
record keeping, communication, publicity materials, web site maintenance, etc. 
 
 
 
 
 
                                                 
41 A review by the HSE of addiction clinical governance is currently underway. 
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3.7.3. Project Management 
A Demonstration of this size and nature required dedicated project management and 
administrative resources.   
 
The results of the stakeholder consultations show that there was a clear vision and strong 
leadership within the Project.  This imbued the roll out with a clear sense of purpose and a 
positive drive to press on and complete.  There were clear signs that the administrative aspect 
of the Project was under resourced.  This was compensated for through collaborative working, 
shared support and goodwill across the organisations that championed the Project.  This is 
unlikely to be sustainable into the future. 
 
Aspects of the project management that worked well: 
 
 Political will and support from the Minister and strategic alignment with the policy 
commitments, e.g. National Drugs Strategy. 
 Clear vision and strong leadership on the part of the Project Lead and anchoring the 
Demonstration within the National Drugs Strategy. 
 Support from senior management within the social inclusion units in the HSE and the 
Department of Health. 
 Drive, energy and enthusiasm from key stakeholders and champions within services 
and health sector. 
 Activation of existing networks and in particular the NGO sector. 
 Preparation and ground work driven by the Chief Pharmacist, the QAG members and 
others within the network of front line organisations that have been calling for 
Naloxone for some time. 
 Good will and inter agency support and cooperation which was crucial to this time 
limited project.  For example, one of the service providers assigned a member of their 
staff to help with record keeping and another supplied administrative/secretarial 
support. 
 Speedy decision making and ready access to information and expertise. 
 Leadership, support and responsiveness of the members of the QAG. 
 Good work ethic and commitment to testing the training materials through an iterative 
methodology through a small core team of trainers. 
 Broad reach, wide dissemination of training and high attendance of representatives 
from the sector of those serving the needs of people vulnerable to overdose and their 
loved ones. 
 Direct access to the pharmaceutical company supplying the product. 
 Rigorous procurement and distribution of supply through a courier network. 
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Aspects of project management requiring attention: 
 
 Whilst firmly acknowledging that the Demonstration Project worked to an agreed tight 
time line the learning indicates that the time and resource constraints had an adverse 
impact on certain aspects of the work.  There were some signs that the Project was 
rushed and under resourced administratively.  A more measured approach would allow 
time for preparation, communication and consultation as mentioned in a previous 
section. 
 Provide adequate resourcing in terms of administration staff and management time.  
The results indicate that three days per week is necessary to manage the roll-out of a 
project of this size.  Full time administrative support is a necessity. 
 Acknowledge the distinctiveness of the four locations as each progressed in 
accordance with its own features and factors.  There were examples of people 
attending training early on and then a lapse of time before they had any opportunity to 
apply their learning.  This calls for more careful timing and sequencing of training 
events.  It also calls for more preparation of GPs, including their briefing, training and 
resourcing, to conduct medical assessments and prescribe Naloxone. 
 Allow time for reflection post training event so as to refine materials and prepare for 
the next event.  There were times when more time was needed to update and refine 
materials for quality assurance purposes. 
 Consider developing and sharing a training calendar (on the website) so that people 
have sight of the time table of Naloxone Training Programme and may choose to 
attend for refresher courses.   
 Achieve consistency in quality of training across a diversity of organisations by 
monitoring and supporting the roll out of training/briefing in service provider locations.  
The active Trainers (31) are calling for support and encouragement, continuous 
professional development (CPD) and quality assurance. 
 Disseminate training packs and resource materials uniformly and consistently across 
the four locations.  This was achieved to an extent by making all materials available on 
line. 
 Continue to respond to the expressed (and some unexpressed) concerns of some 
stakeholders (particularly medical professionals) around the use of Naloxone in its 
current form (e.g. size of dosage, delivery mechanism (injectable) and believed risks of 
reuse?) 
 Access to Naloxone - ensuring that stocks are disbursed in a timely manner. 
 Consider outsourcing of training for future accreditation and maintenance of 
qualifications. 
 Continue discussion/consultation with community pharmacists, PCRS and GPs so that 
the full suite of services and supports are in place in each location. 
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3.7.4. Legislation 
The legislative context is of utmost importance to the Naloxone Demonstration Project.  For 
some stakeholders it was a dominant theme and talking point.  Naloxone is prescription only 
medication and must be prescribed by a GP and stock may only be held by a qualified medic.  
This means that it cannot legally be held in services for emergency use.  This is considered a 
serious limitation by service providers and family members. 
 
Aspects that worked well in terms of the legislative context: 
 
 The Naloxone Demonstration Project alerted all stakeholders to the legislative context 
and raised awareness and understanding of what a prescription only medication is. 
 It provided a space for concerns (e.g. amongst some HSE management and health 
professionals) about the legislation to be expressed.  
 The training was meticulous about the legislative requirements and all those who 
participated were well informed and cognisant of their responsibility.  This proved 
challenging at times especially in instances where trainees found it difficult to 
understand and accept the binds of the legislation and the limitations it presents to the 
full access to Naloxone and preparedness for an overdose emergency. 
 As an Exemption Medicinal Product (EMP), the Chief Pharmacist honoured the 
legislative requirements by ordering the product and maintaining supply records. 
 The Demonstration drew attention to and augmented understanding by stakeholders 
of the status of Naloxone on importation as an EMP as already authorised in the UK. 
 The Project supported the inclusion of Naloxone in public health consultation for 
deregulation of emergency medication (outcome of consultation process is pending). 
 
Aspects of the current legislative arrangements that require attention: 
 
 Acceptance of and working within the current legislation means that all service 
providers must be aware of the reality and follow through on requirements even if 
they doubt their validity.  This requires ongoing training and briefing of front line 
workers to equip them with the competence and confidence to brief the end user 
about Naloxone, as a prescription product.  There has been some uneven 
interpretation of the legislation and some grey areas exist.  This has caused concern 
amongst stakeholders and calls for ongoing robust communication, openness and 
thought leadership if the current legislation prevails42. 
                                                 
42
 The Minister for Health issued regulation on October 23rd 2015.   This provided for the 
supply and administration of specified prescription-only medicinal products without a 
prescription (including naloxone) to a person by a pharmacist or by an individual appointed by a 
listed organisation for the purpose of saving life or reducing severe distress in emergency 
situations.  This is in instances where the pharmacist or individual has completed an approved 
course of training in the administration of such products and the management of any adverse 
reaction.  Medicinal Products (Prescription & Control of Supply) amendment No 2 2015 SI No 
449 www.statutebooks.ie  
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 Constant open dialogue is necessary about the legislative situation that surrounds 
Naloxone.  This is best achieved through formal and informal communication channels, 
to ensure that all are fully briefed and informed, are aware of the regulations and the 
implications of accessing stocks.  This includes a central point of contact, details of 
forms required, payment arrangements, distribution outlets, stocks, etc. 
 
 Building a body of evidence to question and challenge the current legislation, as 
appropriate, through a measured, ethical and evidence based methodology. Areas for 
consideration include: 
 
o Re-regulation of the product as a non-prescription emergency medication to 
enable wider distribution and holding of stock by non-prescribing outlets (e.g. 
pharmacies, service providers, family members). 
o Ensuring appropriate systems to allow service users, staff in service providers 
and families to access the product safely, in tune with regulation and without 
undue hindrance. 
o Decision on distribution outlets: e.g. engaging and training pharmacies as a 
possible distribution outlet that could also brief family members and service 
users in the safe and appropriate use of the product. 
 
3.8 Summary of Chapter Three 
The Naloxone Demonstration Project commenced in February 2015 in four locations (Dublin, 
Waterford/South East, Limerick and Cork).  There was over two years of preparatory work in 
advance of commencement. This included setting up the Quality Advisory Group (QAG), 
development of comprehensive training including resource materials, the Train the Trainer 
component and training programme for front line workers and family members.  
 
The rollout progressed steadily in Dublin and Limerick during 2015 and commenced in 
Waterford towards the end of 2015.  There was active participation by Cork based service 
providers in the Train the Trainer Programme and front line training during the Demonstration 
time line.  However, Cork did not become operational in terms of prescribing of Naloxone 
during the course of the evaluation.   
 
The factors that supported the roll-out included prior awareness of and engagement with the 
Project; the presence of local champions; belief in the efficacy of Naloxone; clear 
communication of the process and referral pathways; acceptance, willingness and availability of 
GPs locally to engage and prescribe Naloxone from the outset and support from the National 
Family Support Network and its membership on the ground locally. The Project also supported 
the inclusion of Naloxone in public health consultations about deregulation of emergency 
medication. The next chapter examines the outcomes and early impact of the Demonstration 
Project. 
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Chapter Four 
Project Outcomes & Early Impact 
 
This chapter sets out the project outcomes and the early impact of the Naloxone 
Demonstration Project.   
 
The Demonstration Project unfolded actively in Dublin and Limerick (with Waterford coming 
on stream later in 2015).  This centred on a small number of championing organisations, mainly 
those serving the needs of vulnerable adults (including people experiencing homelessness and 
addiction) through psycho-social care and support.  
 
4.1 Naloxone Prescriptions 
A total of 95 prescriptions of Naloxone were issued during the Demonstration Project.  The 
majority (67%) of these were issued in Dublin and the remainder (33%) were issued in Limerick.   
 
Six GPs in total were involved in the medical assessment and prescribing of these prescriptions.  
The majority (5) of the GPs are Dublin based and one is based in Limerick. During the time of 
the Demonstration there were no prescriptions issued from the other two Demonstration 
locations, Waterford and Cork.  Towards the end of the Demonstration the GP based in 
Waterford HSE Addiction Team (St Otterans), commenced prescribing and supplying Prenoxad 
™.  Also in this time line the Drug Treatment Programme in the Irish Prison Service activated 
the provision of product in Mountjoy Prison, Dublin.  
 
The Chief Pharmacist holds the records of all prescriptions and patient details safely and 
confidentially in password protected Excel files 
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4.1.1 Dublin    
Of the total 95 prescriptions, 64 prescriptions were issued in Dublin from five service 
providers/locations of Naloxone supply from 03/06/2015 to 04/11/2015: 
 
o 41 (64%) at Merchants Quay Ireland 
o 10 (16%) at Granby Centre 
o 6 (9%) at Haven House (Crosscare) 
o 4 (6%) at St John’s Lane 
o 3 (5%) at Cedar House 
The average is almost 13 products supplied per month 
 
 45 (70%) were prescriptions to male patients. 
o Average age was 35 
 
 19 (30%) were to female patients. 
o Average age was 31 
 All patients were receiving Naloxone for the first time. 
 All patients gave their consent. 
 Risk assessments were conducted by front line workers (7) in the five main service 
providers that the patients had contact with, i.e. Merchants Quay Ireland, Crosscare, 
Cedar House, Granby, and St John’s Lane. 
 
4.1.2 Limerick 
There were 31 prescriptions43 issued in Limerick from two service provider/locations of 
Naloxone supply from 11/04/15 to 29/10/2015.   
 
o Mc Garry House/Novas Initiatives (14) 
o Ana Liffey Drug Project (17) 
 
 20 (65%) were prescriptions to male patients 
o Average age was 37 
 
 11 (35%) were to female patients 
o Average age was 31 
 
 The majority (81%) of patients were receiving Naloxone for the first time and the 
remaining 19% were on their second supply. 
 All patients gave their consent. 
 Risk assessments were conducted by front line workers in the two main service 
providers that the patients had contact with, i.e. Mc Garry House/Novas Initiatives and 
Ana Liffey Drug Project. 
                                                 
43 This includes resupplies of six making it a total of 25 unique patients.  Three of the resupplies were to 
female patients and three to male patients. 
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4.2. Naloxone Training 
An open invitation was extended to all services to attend the Naloxone and Overdose Training.  
Stakeholders became aware of the training through the Project Lead, the National Family 
Support Network (NFSN) and the network of front line workers operating throughout 
addiction and homeless services. This ensured that a diverse range of organisations and 
individuals with different skills, knowledge and experience attended the training. This ensured 
inclusion and a broad base of supporters and raised awareness of Naloxone and managing a 
drug overdose incident. 
 
The Chief Pharmacist is the centre point for storage of all returned records of training sessions.  
They are held safely and confidentially in paper and/or Excel files. 
 
Train the Trainer 
Thirty-one people from relevant service providing organisations participated in the two-day 
Train the Trainer Programme.  The result is a cohort of professional people within services 
primed and ready to cascade the Naloxone training to their peers as a safeguard to prevent 
opioid related deaths with the population of services users and beyond.  Many trainers are 
incorporating the learning from the Naloxone training into their repertoire of harm 
minimisation tools.  This strengthening of awareness about overdose and understanding of the 
precision steps to take in the event of an overdose is a significant positive outcome of the 
Demonstration Project. 
 
4.2.1 Briefing of Service Users 
 
Of the thirty-one trainers, approximately one third proceeded to apply their learning to cascade 
the Naloxone training to their peers, service users and family members.   
 
It is estimated that some services will have up to one hundred service users that they may 
target for the Naloxone training on site.  This is being achieved through a range of methods.   
These methods include outreach to service users in their homes in some instances, 
spontaneously catching service users at opportune moments when they are attending a service 
and/or through prearranged Naloxone briefings on site.  The choice of method is dependent 
on the mindset, readiness and capacity of service users to absorb the briefing content and 
attend for a medical assessment.   A sizeable cohort of service users is deemed, by service 
providers, to be too chaotic in their drug use and poor health to attend the briefing.  The 
reality is that front line workers make judgement calls as to who to and how to deliver the 
Naloxone briefing during the course of their work.  Factors that enable this to proceed include 
the ready availability of a GP on site and confidence that the Naloxone is ready to be 
prescribed as necessary.  There are also practical considerations such as availability of a room 
to conduct the briefing and necessary resource materials, e.g. lap top, monitor or TV to show 
video. 
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4.2.2 Front Line Training 
 
In line with stated objectives, by the end of evaluation period October 2015, close to 60044 
people had participated in the Naloxone training that was delivered during the time frame of 
the Demonstration Project.  
 
Those who participated in the training were mainly front line personnel working in services 
across the Demonstration sites (Dublin, Limerick, Cork and Waterford).  This includes over fifty 
service providing organisations (including front line workers in a range of homeless and social 
care settings, HSE and Irish Prison Service personnel, GPs, pharmacists and outreach workers).  
These frontline workers are briefed in the role and use of Naloxone as an opioid 
antidote/reverser. In addition, 79 family members have been trained by the Family Support 
Network (FSN) with the support of local frontline workers. 
 
The vast majority were invited to complete a pre and post training evaluation sheet offering 
their response to a set of six questions.  These questions were anchored on the Opioid 
Overdose Knowledge Scale (OOKS) and Opioid Overdose Attitude Scale (OOAS).   They 
captured the degree of confidence post training in (a) using the kit and (b) providing 
information on overdose and Naloxone administration. 
 
These questions centred on the following: 
 
 Participant profile 
 Factors that increase the risk of a heroin overdose 
 Indicators of an opioid overdose 
 Actions to take when managing a heroin overdose 
 
As part of the evaluation methodology as at July 2015 the pre and post evaluations of 492 
participants were entered into an SPSS45 database.  The results show significant positive shifts 
in knowledge and awareness of how to recognise and manage an overdose situation and 
administer Naloxone correctly 
 
 
 
 
 
 
 
 
 
                                                 
44 The completed evaluation sheets for 492 were included in the SPSS analysis for this evaluation.  This 
was completed in August 2015.  Further numbers were trained in the period August to October 2015. 
Thus the actual number of people trained is closer to 600. 
45 Statistical Package for the Social Sciences (SPSS) 
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The summary results of the SPSS analysis are as follows: 
 
 The majority of participants (77%) were Dublin based.  A further 10% were Cork based, 
10% were in Waterford and 3% were Limerick based. 
 The participants came from the full range of services that support the needs of those 
affected by problematic drug use, e.g. HSE, pharmacists, the Prison Service, homeless, 
hostel and addiction service providers, health care, nursing personnel and students of 
addiction studies. 
 The majority (75%) had previously completed CPR/BLS training. It is unknown how 
recent that this training was completed for each.  Those that had not completed this 
training were advised to do so. 
 There was good understanding pre training of the factors that increase the risk of a 
heroin overdose (ranging from 72% to 95% across the eight factors measured – see 
table one).  This had shifted upwards by a small number of percentage points post 
training for five factors.  It remained the same for two and decreased slightly for two 
factors, i.e. taking larger than usual doses of heroin and using heroin after not having 
done so for awhile (see table one).  
 The majority understand the importance of calling an ambulance in the event of an 
overdose. After receiving the training this rose to 99% compared to 95% before the 
training. 
 The majority understand the importance of staying with a person who is experiencing 
an overdose and waiting until the ambulance arrives to tend to the person. After 
receiving training this rose to 98% compared to 95% before the training. 
 Awareness about the effects of Naloxone improved as a result of the training (see table 
three).  Understanding about responding to an overdose situation through use of the 
recovery position and mouth to mouth resuscitation if necessary also improved. 
 The majority understand that it is not appropriate to give stimulants or inject with salt 
solution or give milk to a person experiencing an overdose.  
 The feedback indicated that over half (54%) felt very confident to use Naloxone after 
the training.   A further 38% felt somewhat confident, 7% were a little confident and1% 
were not confident at all.  
 Over half (57%) indicated that they felt very confident, as a result of the training, to 
provide information on overdose and Naloxone administration.  A further 35% were 
somewhat confident, 7% were a little confident and1% were not confident at all.  
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Table One: Factors that Increase the Risk of a Heroin Overdose (n=49246) 
 
 Pre Training Post Training 
1. Taking larger than usual doses of heroin 95% 93% 
2. Switching from smoking to injecting heroin 89% 90% 
3. Using heroin with other substances 89% 92% 
4. Using heroin again after a Detox treatment 93% 93% 
5. Increase in heroin purity 90% 91% 
6. Using heroin again after not having done so for a while 94% 93% 
7. Using heroin again after release from prison 83% 92% 
8. Using heroin alone when no one else is present 72% 87% 
 
 
 
 
Table Two: Indicators of an Opioid Overdose (n=492) 
(Respondents beliefs pre training47) 
 
 Respondents who believed that this was a indicator of an 
overdose 
Having blood shot eyes 17% 
Very small pupils 69% 
Agitated behaviour 19% 
Slow/shallow breathing 86% 
Lips, hands or feet turning 
blue 
85% 
Loss of consciousness 92% 
Unresponsive 94% 
Fitting 37% 
Deep Snoring 49% 
Rapid Heart beat 29% 
 
 
 
 
 
 
 
                                                 
46 This is the number of completed evaluation sheets included in the SPSS analysis for this evaluation. 
This was completed in August 2015.  Further numbers were trained in the period August to October 
2015. Thus the actual number of people trained is closer to 600. 
47 Respondents beliefs post training were not collected.  It is recommended that future evaluation sheets 
be updated to capture this data. 
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Table Three: Truths About Effectively Managing An Overdose Situation 
 
 Pre Training 
’True’ 
Post Training 
‘True’ 
If the first dose of naloxone has no effect a second dose can be 
given 
52% 94% 
The effect of naloxone is shorter than the effect of heroin and 
methadone 
47% 87% 
There is no need to call an ambulance if I know how to manage 
an overdose 
3% 1% 
After recovering from an opioid overdose the person must not 
take any heroin, but it is ok to drink alcohol or take sleeping pills 
5% 16% 
A person may overdose again even after having received 
naloxone 
7548% 92% 
 
   
 
Table Four: Things to do to Manage an Overdose Situation (n=492) 
 
 Pre Training Post Training 
1. Call an ambulance 95%  99% 
2. Stay with the person until ambulance arrives 95%  98% 
3. Mouth to Mouth resuscitation 48% 71% 
4. Place correctly in the recovery position 88% 92% 
5. Give naloxone 83% 94% 
6. Check for breathing 91% 93% 
 
 
4.2.3 Family Members 
 
The results of the SPSS analysis for those who attended the training sessions organised by the 
NFSN and dedicated to family members (76) differ slightly from the results for the full 
population.  A slightly higher percentage, i.e. 66% of family members felt very confident to use 
Naloxone after the training.   A further 30% felt somewhat confident and 3% was a little 
confident.  Sixty-three percent of family members indicated that they felt very confident, as a 
result of the training, to provide information on overdose and Naloxone administration.  A 
further 26% were somewhat confident, 9% were a little confident and1% were not confident 
at all.  
 
                                                 
48 22% indicated that they did not know and after training this had shifted positively to no do not knows, 
i.e. 98% knew that it is possible to overdose again even after having received Naloxone. 
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We cannot be certain of the precise reasons for this variation and the higher confidence levels 
amongst family members when compared with others who attended the training, e.g. health 
professionals, service providers.   
Contributory factors may be the longer time spent training and the tailoring of the training for 
family members.  This includes the extra time and process devoted to experiential learning and 
discussion of the emotional aspects of coping with and managing an overdose situation.   
Sessions also allowed for continuous discussion and asking of questions and family members 
had the chance to practice the recovery position and watch a demonstration of CPR. They also 
had lots of time to practise injecting on oranges. 
This confirms the commitment of family members and their wish to be prepared and in control 
in the event of an overdose situation involving their loved one.  The consultations with family 
members conducted as part of the evaluation verify this sense of solace and confidence that 
family members feel.  This is irrespective of whether or not they ever actually use Naloxone. 
 
Overall the results show that the training has had a significant positive impact on awareness 
and knowledge of overdose and ability to manage overdose situations including the 
administration of Naloxone. 
 
The results also signal that some further refinement of the training and after training support is 
required to ensure that all those who participate feel fully confident in their own competence in 
managing overdose situations and in the use of Naloxone.  This includes adjusting the training 
(content and time) to ensure full coverage and competence in relation to CPR and practicing 
the administration of Naloxone.  This has been addressed and one of the lead trainers has 
completed instruction and is now a qualified and accredited CPR instructor. The results also 
point to a need for ongoing support and refresher training into the future. 
 
4.2.4 Feedback from Trainees 
Qualitative comments about the training written onto evaluation sheets included the following: 
 
Very thorough training, succinct and accessible 
Training was a bit rushed in the end.  Do not feel confident showing someone else.   
I think day long training on CPR (something similar to the 1HitKit training) would be 
beneficial.  
Need more training in the area as there are obviously grey areas, e.g. blood spatters. 
Training was clear and well delivered.   
Really helpful – thank you 
Very good and informative  
The training was very thorough. 
Visual aids are very good and work well with service users 
Very relevant for all staff and service users 
Very good, information given very clearly 
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Arising from trainee feedback aspects of the training that require attention (many of which 
have been addressed already) include: 
 
 A call for CPR training to be delivered by a qualified CPR trainer and full coverage and 
practice of CPR during the training. 
 Some concerns about the use of an injectable version of the product being normalised. 
 A call to consider safe non-injectable options. 
 Some concerns about distribution of and access to Naloxone, e.g. in the regions where 
there was no known GP ready and available to prescribe. 
 Building space into the training for questions and answers and more discussion about 
managing overdose situations and the effect of Naloxone in reducing the number of 
fatal overdoses. 
 
4.3 Use of Naloxone Kits in Overdose Situations  
During the course of the Demonstration Project there were five administrations of Naloxone 
and potentially fatal overdoses were prevented for the five males involved.  The combined 
case stories are presented below. 
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Combined Case Stories of Naloxone Administration during the Demonstration: 
 Five males were administered Naloxone as a measure to reverse accidental overdose.  
The age range was 31 to 50 and.(This fits with NDRDI data) 
 Four of the Naloxone administrations were administered by front line workers and one 
was administered peer to peer.  All had participated in the Naloxone training delivered 
during the Demonstration Project. 
 Three were administered by females and two by males. 
 Four of the administrations were on the premises of service providers or within the 
immediate surrounding area, e.g. court yard area outside the building.  
 In each of the incidents the Naloxone was administered to a person other than to 
whom it had been prescribed.  This suggests that the availability of and easy access to 
Naloxone was crucial to the successful reversal of overdose.   
 In two instances more than one dose of Naloxone was administered from the five dose 
syringe.  This was judged necessary during the wait for the ambulance to arrive and 
deemed to work well. 
 In all instances at least one person or staff member remained with the patient until 
emergency services arrived. 
 In all instances an ambulance was called and arrived at the scene.   
 In two instances the patient was admitted to hospital and discharged after a short 
period of observation. 
 The front line workers managed the situations effectively and followed through on the 
precise steps that they had learnt about and practised during their training. 
 In four of the five cases the service providing organisations completed the appropriate 
post incident paper work (F.5.49), debriefings and review.  Some of these reports 
contained more detail than others.  All indicated that they learnt from the experience 
and felt that the training was invaluable in preparing them to respond appropriately. 
 Stocks of Naloxone were replenished in all incidents with some delay for supplies to 
Limerick. 
 Those consulted (3) as part of this evaluation all reported a sense of enhanced 
empowerment and surety after the Naloxone administration.  Their confidence in the 
procedure for managing an overdose event had increased as had their sense of their 
own confidence in being useful in such a situation.  
                                                 
49 The Form 5 (F.5) is an Incident Follow Up Report which must be completed post administration of 
Naloxone.  It contains details of the incident, profile of the person who overdosed, actions taken, e.g. 
calling ambulance, CPR, waiting with the person and whether the person attended hospital, etc. 
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  These interviews were held soon after each event (i.e. within a week) and each 
possessed a strong sense of pride and relief that they had contributed to saving a life.  
The harrowing reality of witnessing an overdose was palpable as was the positive sense 
of being able to take appropriate action to prevent a fatal overdose.   
According to one front line worker: 
‘It was my first time administering Naloxone.  I was happy to see the Naloxone work and to observe 
the service user’s vital signs returning to normal.  Two other services users witnessed it being 
administered to their friend.  They saw first-hand what Naloxone can do.  Since the administration 
four more service users have signed up for the Naloxone briefing and to receive their prescription’.   
 
Another front line worker, verified the above saying ‘clients understand Naloxone now, they know 
how to use it and it is important that they have access to it’. 
 
 In one incident staff found trying to open the Naloxone pack (whilst also wearing 
gloves) a bit difficult.  They suggested ‘an easy to grab tab might work better for easy 
opening, as opposed to a twist and break seal’. 
 
4.4 Summary of Chapter Four 
During the Demonstration Project five deaths were prevented in the period up to October 31st 
2015. These deaths were prevented through the appropriate administration of Naloxone after 
determining that the individuals in question were showing signs of opioid overdose. 
 
Six GPs were involved in issuing and supply of 95 prescriptions for Naloxone (Prenoxad ™) 
between the Dublin and Limerick locations.  This implies that 95 service users, at high risk of 
overdose, completed the Naloxone briefing as part of a harm minimisation programme.  They 
now have access to Naloxone on their person for administration in the event of an overdose.   
 
Thirty-one participants completed the Train the Trainer modules.   Close to 600 others, mainly 
frontline workers from a wide range of organisations, and family members, were trained in 
recognising and effectively managing an overdose situation and responding to these situations 
with the use of Naloxone.   
 
The results show positive shifts in awareness and attitudes and knowledge of how to recognise 
and manage an overdose situation and administer Naloxone correctly.  The majority of 
participants have gained in confidence to manage such an event.  The learning indicates that 
further refinement of the training and after training support is required to ensure that all those 
who participate feel fully confident in their own competence in managing overdose situations 
and in the use of Naloxone.   
 
The next chapter draws conclusions from the research and makes recommendations for the 
roll-out of Naloxone. 
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Chapter Five 
Conclusions and Recommendations 
This chapter draws together the overall results of the evaluation of the Demonstration Project.  
It sets out recommendations to guide decision making into the future.   The reach of the 
Demonstration is highlighted, alongside principle learning.  This is the nature of a 
demonstration project as its primary purpose was to place a spotlight on the strengths, 
breakthroughs and the learning in order to inform decision making and future planning. 
 
5.1 Overall Conclusions 
The Naloxone Demonstration Project, a harm reduction measure, was supported by the 
National Social Inclusion Office (Primary Care) of the HSE and fits within the suite of actions 
under the National Drugs Strategy.  
The Demonstration successfully contributed to the reversal of potentially fatal overdoses in 
five (5) separate situations50 through the administration of Naloxone in accordance with the set 
procedure for managing overdose situations.  These potential deaths were prevented by front 
line workers and/or peers activating the effective overdose management procedures learnt 
during their Naloxone training during 2015.  Table 5.1 shows comparison data across a number 
of regions/countries. 
 
Table 5.1.  Deaths Prevented when Naloxone Used – Comparison Across Different Regions/Countries 
 
Source Death Prevented : lives lost 
when Naloxone used 
Deaths Prevented : lives lost 
when Naloxone not used 
USA Los Angeles (Wagner et al 
2010) 
26:4 
(87%)51 
Na 
USA San Francisco (Seal 2005) 15:0 
(100%) 
Na 
USA New York (Galea 2006) 10: 0 
(100%) 
Na 
USA Baltimore (Tobin 2009) 19: 0 
(100%) 
Na 
Wales (Bennett 2011) 21:1 
(96%) 
38:1 
 
Scotland Glasgow (Shaw 2008) 10:1 
(95%) 
Na 
Scotland Lananhshire (McCauley 
2010) 
2:1 
(67%) 
Na 
U.K. South east/south west, 
midland/.north (Stray 2008) 
12:0 
(100%) 
6:1 
 
Ireland demonstration project 5:0 within a five month 
period52  
(100%) 
Na 
                                                 
50
 A further three deaths were prevented in Ireland with the use of Naloxone in the period following this 
evaluation and post the Demonstration period, i.e. November 2015 – January 2016. 
51 A total of 35 overdose events were recorded but the outcomes in respect of 5 were unknown. 
52 There were three more reported administrations of Naloxone in the period after this evaluation was 
completed, i.e. November – December 2015. 
51
Evaluaon of the HSE Naloxone Demonstraon Project
52 | P a g e  
 
The evaluation of the Naloxone Demonstration Project formally commenced in June 2015.   
The field work was action research oriented, given the nature of the Demonstration Project, 
and was conducted between June and October 2015.   
 
The overall conclusion is that the Demonstration Project raised awareness of overdose and 
generated knowledge and competence to manage an overdose situation safely and effectively 
with the use of Naloxone.  Five, potentially fatal, overdoses were reversed.   
 
The project was a good return of investment (€62,500) in that it provided overdose 
management training to over 600 people across the full suite of services providers and support 
organisations that work with illicit drug users.  It expanded conversations and activated 
learning about overdose and the potential of Naloxone in overdose situations.  It was an 
inclusive project and activated much goodwill and networking across the social inclusion 
sector.    
 
There was strong commitment to the Naloxone Demonstration amongst service users, service 
providers and family members.  It progressed swiftly in Dublin with Naloxone prescribed the 
day after the Minister’s announcement.  Limerick followed in August 2015 and Waterford, in 
November 2015.   
 
The main drivers were the NGOs supported by the Project Lead and a circle of supportive 
champions including medical and allied professionals with a history and understanding of 
working within a social inclusion ethos. 
 
The Demonstration stimulated conversation and raised questions about how we work with 
drug users, how we support their families and the suite of services and supports provided.  It 
has opened discussion and progressed discussion about governance, ethics, procurement, 
supply and safe storage. 
 
Naloxone is, at its simplest, a pharmaceutical product with the capacity to reverse the effects 
of an opioid overdose.  The results of this evaluation indicate that Naloxone, as a concept, is 
also a catalyst for positive change in behaviour in drug use and harm minimisation.  It fits 
within the suite of supports, services and treatment for drug users, i.e. harm minimisation, 
Opioid Substitution Treatment (OST), needle exchange, detoxification and treatment of 
addiction  It is a valuable addition to the toolkit of harm minimisation and forms part of an 
overall strategy to affect a change in opioid related drug deaths. 
 
The benefits of Naloxone is more widely known and accepted by many in its current 
formulation as a prefilled injectable device.  
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It is envisaged that as there is now an FDA approved Itranasal formulation,that the project will 
seek to include such a device into the new legislation once there is a product licensed to the 
European market. 
 
Naloxone has been most welcomed by family members and front line workers who work with 
those at risk of overdose. 
 
5.2. Impact 
The Demonstration Project has had significant outcomes and early impact in a number of ways.  
These include: 
 Awareness raising about the correct procedures in an overdose situation amongst an 
estimated 700 front line staff, family members and service users. The project has 
expanded the conversation about overdose, being at risk and the drills and actions that 
we can use to manage these situations effectively.   
 The numbers and range of services that participated in the training, which resulted in 
knowledge, understanding and networking outcomes that extends beyond Naloxone. 
 Providing families with peace of mind. It provides a sense of control, preparedness and 
reassurance to family members who have loved ones at risk of overdose. 
 Empowering service users to help themselves and peers. The Naloxone product and 
the accompanying briefing is a way of opening up conversations with drug users who 
are at risk of overdose.  It is a tangible activator or conversation starter that supports 
front line workers in their harm reduction work. 
 Six GPs have prescribed Naloxone consistently over the course of the Demonstration, 
five in Dublin and one in Limerick. A seventh GP commenced prescribing in Waterford 
towards the latter end of the Demonstration time period. 
 Ninety-five people have been prescribed Naloxone with more coming on stream as 
prescription mechanisms bed down in each location. 
 Naloxone has been administered on five separate occasions during the second half of 
2015 and five fatal overdoses were reversed (three in Dublin and two in Limerick).  
These administrations have engendered a positive feeling of empowerment and 
possibility amongst all involved. 
 
5.3. Learning 
The Demonstration Project was open and iterative and generated a lot of learning during 
implementation.   
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Commitment 
 
There was commitment to the Demonstration Project across the range of organisations that 
have been calling for this intervention for some time.  The Project was welcomed and there 
was appreciation of the movement and action to assess the use of Naloxone in Ireland.   
 
Some stakeholders showed signs of doubt and hesitancy and efforts were made to draw these 
into the discussion and decision making. It is important that this continues and that there is 
dedicated time, inclusive communication and careful consultation to ensure that all 
stakeholders contribute and shape the optimal model for future roll out of Naloxone in Ireland.  
This fits with the learning from other countries.   
 
It is important to draw all stakeholders (medical, pharmaceutical, social care, psychological, etc.) 
together and share evidence to influence positive change, as ethically and clinically 
appropriate, e.g. change in formulation of the Naloxone from injectable to nasal and any 
progressive changes in the legislation. 
 
Collaboration 
 
There was good collaboration and working between members of the Quality Advisory Group, 
the Project Lead and those service providers working directly with people at high risk of 
overdose. There were many examples of organisations working together and sharing their 
resources in the interest of the Naloxone Demonstration Project and for the greater good.  
There is scope to strengthen this collaboration even further through governance structures 
such as the QAG and networking with appropriate professional bodies. 
 
Governance and Management 
 
The Project was under resourced in terms of the personnel necessary to manage and 
administer a project of this size and influence, e.g. ongoing communication with stakeholders, 
precision data collection and record keeping, training scheduling and structuring, refinement of 
materials, preparation and dissemination of resources and everyday logistics. 
 
Further development needs include: 
 
 Developing and managing systems to monitor the training as it rolls out, e.g. tracking 
and supporting participants and delivery in outreach locations. 
 Developing and managing systems for effective distribution of Naloxone, extending its 
reach and looking at ways to reach those most at risk of opioid overdose. 
 Developing and managing systems to monitor prescriptions and related administration 
uniformly across the sites. 
 Developing and managing communication systems to respond to questions and 
concerns of managers, front line workers, service users and family members.  A central 
reliable and professional communication point is important given the changing 
landscape of drug addiction and the questions and concerns that arise. 
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The QAG provided a useful sounding board and support to the Project Lead.  There is scope to 
validate and strengthen this capacity through stronger terms of reference and a broader 
membership.  Any intentions to raise awareness and value of Naloxone will be strengthened by 
including medical expertise and HSE representation across the four locations and beyond. 
Practicalities 
 
The learning from the Demonstration alerts us to many practicalities that warrant attention as 
we continue to include Naloxone in the suite of supports that fit within the harm minimisation 
model of operation.  This learning relates to timing or sequencing of Naloxone training, access 
to a GP and access to a supply of Naloxone for immediate prescription.  There were times 
during the Demonstration when training was completed too far in advance of the availability of 
Naloxone.   
  
To maximise momentum the training of front line workers must be accompanied by availability 
of Naloxone on site in their services and availability of a GP to conduct the medical assessment 
and prescribe. The availability or easy access to a GP is an important component of service 
provision, irrespective of the ways in which Naloxone is available or distributed into the future.  
Family members are calling for reassurance in this regard. 
 
It is also important that all the relevant resources materials, e.g. training packs, visual aids, 
DVDs, record forms and briefing documents are readily available and personnel fully 
understand their fit and use.  Services must also have access to the necessary lap tops and/or 
monitors to play the training DVD.  It is good practice to have Naloxone posters/brochures 
displayed in full visibility on site in service provider receptions and/or open areas.  
 
 This ensures continuity and conveys the messages of harm minimisation and safety openly 
within each service.  This invites curiosity and raises awareness of Naloxone and its purpose 
amongst those who are as yet unaware. 
 
Cascade Model  
 
The evaluation shows that the cascade model has merits, particularly in terms of efficiency and 
inclusiveness of training delivery.  It is useful to consider supplementary ways to achieve a 
systematic approach to the delivery of training across the range of stakeholders, variety of 
organisations and diversity of workers coming forward for training.   
 
The trainers were open to feedback and the training materials were refined as the project 
unfolded.  All materials are available online at www.drugs.ie  along with open and clear 
information from the Chief Pharmacist about the Demonstration Project and its purpose. 
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Prisons 
 
Prisoners are accepted as being a high risk group for accidental overdose particularly within the 
first two to four weeks post release. The Irish Prison Service participated in the roll-out of the 
training and some delays were experienced in the prescribing of Naloxone to prisoners 
pending release.  These were resolved towards the end of the Demonstration. 
 
Supply and Distribution of Naloxone 
 
The majority of stakeholders believe that the current legislation is a barrier to the wider 
availability of and access to Naloxone.  Currently its use requires a prescription. This means 
that it cannot be held safely in stock by families or service providers for use in the event of an 
emergency.  The five administrations that occurred during the Demonstration indicate that the 
freedom to hold/store Naloxone carefully and safely in assigned locations is more in harmony 
with the reality as it currently stands. 
To enhance distribution and access to Naloxone, an amendment to the Prescriptions 
Regulations was required and this was achieved in October 2015. This amendment may serve 
to enable exemption from prescription control of a medicinal product, e.g. in a specific 
establishment by a person who has completed certified training. Such training could be 
accredited and a register of those who successfully completed the training could be 
maintained.  This could be a safe, practical and cost effective way to go into the future. 
For people not on the Central Treatment List or known to the addiction services it was 
suggested that it may be possible to work with select pharmacies involved in the needle 
exchange programme.  This could work on the basis of an assessment leading to the hand out 
of a Naloxone pack to an individual with selected doctors subsequently issuing the necessary 
prescription. Such a methodology would require a clinical policy to ensure that doctors were in 
agreement and that correct and robust protocols were in place to allow for issuing a 
prescription after the event. 
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5.4 Recommendations 
The following are the recommendations based on the results of the evaluation of the 
Demonstration Project.  These recommendations centre on communication, consultation, 
training design, robust research and planning for future roll out and distribution of Naloxone in 
Ireland.   
 
The recommendations are set out in priority order of necessary action. 
 
Recommendation One - Communication & Consideration 
We recommend that the results of this evaluation are given careful consideration in advance of 
decision making for the future roll out of Naloxone.  To expedite and structure this period of 
consideration we recommend that the results are discussed, early in 2016, within the QAG and 
the National Social Inclusion Unit within the HSE.  The purpose is to inform the action plan for 
the future. 
 
Recommendation Two - Governance 
We recommend that the QAG be strengthened by broadening its membership to include wider 
clinical expertise and clinical governance and more regional representation.  The terms of 
reference of the QAG should be revisited and revised accordingly. 
 
The first task of this strengthened QAG will be to discuss possible options as to the best way 
forward for Naloxone and agree the strategy to achieve this.  One option is continuance under 
the current legislation.  Another is to develop a comprehensive case/strategy for reregulation.  
This will take time, preparation and a careful plan. Another option is to explore the availability, 
cost, distribution and training implications of an intranasal formulation of the product.  All 
options should be accompanied by a firm action research plan (see also recommendation six) 
overseen by the QAG. 
 
Recommendation Three - Planning and Preparation for Future Roll Out 
We recommend continuance of the roll out of Naloxone in a measured, phased and strategic 
way with attention on the Waterford/South East and Cork in the first instance.  We 
recommend dedicated resources and personnel assigned to Naloxone roll out in each region. 
 
We recommend continued support to build on the ground work completed in Waterford and 
draw Cork further into the fold.  The rationale is to achieve an even pace and reach across all 
four original Demonstration areas, open out discussion and maximise the learning from the 
evaluation.  This will pave the way to progress to other areas with a clearer plan of action and 
sense of steps necessary, i.e. communication, training, distribution, administration, support, 
monitoring, academic research, etc. 
 
We recommend that the phased roll out be driven by the Chief Pharmacist and commence 
with an initial briefing/consultation with the HSE and relevant stakeholders in each location.  
These stakeholders include professional bodies, GPs, pharmacists, clinical nurses and social 
care workers. The content of this briefing will be informed by the results of this evaluation.  
The purpose is to raise awareness of Naloxone and prepare for the next phase of roll out. 
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We recommend drawing in one other region, based on the NDRDI data, over the next twelve 
months.   Following a favourable review of progress further roll out nationally might then 
proceed. 
 
We recommend that there is specific administrative support dedicated to the Naloxone roll 
out.  This is vital given the precision and vigilance that is required to comply with the 
collection, collation and management of the full range of forms (e.g. F1 – F5), 
patient/prescription data and training records. This calls for a dedicated role with responsibility 
for issuing forms, following up on forms/records, maintaining a secure data base and being the 
contact point for all data relevant to Naloxone distribution. 
 
Recommendation Four - Refining the Training  
We recommend continuance of the Naloxone Training incorporating the learning from this 
evaluation.  This includes refinements to the scheduling/timing and administration of future 
training for front line workers and briefing of service users.  
 
We recommend that the training be accredited by an appropriate body.  This is already in train 
in consultation with the Pharmaceutical Society of Ireland. 
 
We recommend that a training schedule be prepared and disseminated prior to delivery of any 
further training.  This could communicate the nature of the training, aims, learning objectives 
and timetable across regions. 
 
The Train the Trainer component achieves optimal effect when participants have an 
opportunity to practise as soon as possible after receiving the training when their newly 
acquired knowledge and skills are fresh (ideally within three months).    
We recommend that this aspect of timing (i.e. early opportunity to apply the new skills in the 
work place) is given careful consideration in the scheduling of future training programmes. The 
current cohort of trainers is a ready and able resource to deliver future training subject to 
refresher training, clarity of purpose/role and ongoing central support. 
 
We recommend that accredited CPR training, delivered by a qualified and accredited tutor(s), is 
built into the training programme.  This is already being introduced. 
 
We recommend that opportunities for refresher training, peer support and reflective practice 
be built into the suite of future training.   
 
We recommend that the collaborative work with the NFSN continues so as to include family 
members in all future training and development events.  
 
We recommend ongoing evaluation of all future training.  The OOKS and OOAS pre and post 
tools have worked well and should continue to be used to gauge progress.  It is important that 
all completed training evaluation forms are monitored and analysed regularly to note the 
quality of training and any adjustments necessary. 
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We recommend that the pre and post training evaluation forms are modified to include 
participant profile data, e.g. service type, qualification and length of experience, CPR training 
completed, when completed and accrediting body.  This will build a robust data bank that will 
facilitate full analysis of training participation and competence by region, qualification, etc. 
 
Recommendation Five – Briefing of Service Users  
We recommend that the training/briefing of service users in the use of Naloxone continues 
mindful of the learning from the Demonstration.  This includes noting and working to address 
the challenges in reaching and drawing in service users most at risk of accidental overdose and 
those currently beyond the reach of services (i.e. acutely marginalised as a result of their 
addictions and life events). 
 
We recommend that the briefing of service users is monitored carefully and supported.  Given 
the somewhat spontaneous and understandably opportunistic nature of the briefing of some 
service users it is important that front line staff members are supported to achieve quality and 
consistency in their delivery.  This includes easy access to resource materials and support to 
deliver messages/information briefly and succinctly in a range of outreach settings.  It is also 
important to align all briefings with access to the required medical assessment/GP and 
Naloxone prescription. 
 
We recommend that all front line workers are trained and supported to work with their hard to 
reach clients. This includes space and opportunity to discuss, work through and find solutions 
to the challenges that they encounter in the course of their harm minimisation work, e.g. 
service user capacity, readiness, willingness, perceptions of Naloxone, etc. 
 
We recommend that specific attention is placed on monitoring the service users briefed and 
prescribed Naloxone and tracking their health, well being and drug related behaviour over time, 
e.g. through replenishment records, repeat overdose incidents, etc.  Currently all those 
participating in the Naloxone programme have given their consent to the sharing of their data 
for monitoring purposes.  It is important that this aspect of practice continues.  This links to the 
research recommended in recommendation six. 
 
Recommendation Six – Research, Tracking and Monitoring 
We recommend continued research in Ireland in relation to Naloxone.  This will be usefully 
informed by the meticulous tracking of prescriptions, risk analysis, medical assessments, 
number of overdose incidents and Naloxone replenishments.  A central theme will be the 
monitoring of the effect of Naloxone in reducing the number of fatal overdoses.  We 
recommend that the research is multi-disciplinary and is overseen by the QAG with a particular 
emphasis on clinical governance.  Partnering with an academic establishment or research 
organisation will drive and support future research. 
 
We recommend quarterly meta-analysis of the F2 - risk assessment forms and F5 – post 
incident forms to note any patterns in medical risk, drug related behaviour, frequency and 
features of overdose.  These F2s and F5s alongside the excel spread sheets of prescriptions 
and replenishments will form an important body of data that lends itself to useful research 
over time into the patterns of behaviour and health within that cohort of drug users.   
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To this end it is important that there is continued vigilance in full completion of these records 
by all those responsible, i.e. pharmacists, GPs and front line workers. 
 
We recommend continuing the good work that commenced during the Demonstration in 
cultivating the connections/relationships with peers in other countries implementing Naloxone, 
e.g. Wales, Scotland.  This is with a view to ensuring a robust and progressive Irish contribution 
to the body of international knowledge and understanding of what is working well and shared 
learning from practice elsewhere. 
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Appendix One:  
Membership of the Quality Advisory Group – Naloxone Demonstration Project 
 
 
 Denis O’ Driscoll, Chief Pharmacist, Addiction Services, HSE 
 Tim Bingham, National Liaison Pharmacy Worker (HSE) 
 Joseph Doyle, HSE Social Inclusion 
 Megan O’ Leary, Development Coordinator, National Family Support Network (NFSN) 
 Tony Duffin, Director, Ana Liffey Drug Project 
 Dawn Russell, Ana Liffey Drug Project 
 Mark Kennedy, Head of Day Services, Merchants Quay Ireland 
 Emily Reaper, UISCE (Union for Improved Services, Communication and Education) 
  
61
Evaluaon of the HSE Naloxone Demonstraon Project
62 | P a g e  
 
Appendix Two:  
Photographic Exhibition for International Overdose Awareness Day 2016 
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